

1 **Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and**
2 **immunocompromised individuals**

3

4 Katlyn Lederer^{1,2}, Kalpana Parvathaneni^{1,3,4,13}, Mark M. Painter^{1,5,13}, Emily Bettini^{1,2}, Divyansh
5 Agarwal⁶, Kendall A. Lundgreen², Madison Weirick^{1,2}, Rishi R. Goel^{1,5}, Xiaoming Xu^{1,4},
6 Elizabeth M. Drapeau^{1,2}, Sigrid Gouma^{1,2}, Allison R. Greenplate^{1,5}, Carole Le Coz^{1,7}, Neil
7 Romberg^{1,7}, Lisa Jones⁸, Mark Rosen⁸, Behdad Besharatian⁹, Mary Kaminiski¹⁰, Daniela
8 Weiskopf¹¹, Alessandro Sette^{11,12}, Scott E. Hensley^{1,2}, Paul Bates², E. John Wherry^{1,5}, Ali Najji^{1,10},
9 Vijay Bhoj^{1,3,4}, Michela Locci^{1,2,14}.

10

11 ¹ Institute for Immunology, Perelman School of Medicine, University of Pennsylvania,
12 Philadelphia, Pennsylvania, USA.

13 ² Department of Microbiology, Perelman School of Medicine, University of Pennsylvania,
14 Philadelphia, Pennsylvania, USA.

15 ³ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of
16 Pennsylvania, Philadelphia, Pennsylvania, USA.

17 ⁴ Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania,
18 Philadelphia, Pennsylvania, USA.

19 ⁵ Department of Systems Pharmacology and Translational Therapeutics, Perelman School of
20 Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

21 ⁶ Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston,
22 Massachusetts, USA.

23 ⁷ Division of Immunology and Allergy, Children's Hospital of Philadelphia, Philadelphia,
24 Pennsylvania, USA.

25 ⁸ Department of Radiology, Division of Medicine, University of Pennsylvania, Philadelphia,
26 Pennsylvania, USA.

27 ⁹ Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
28 Philadelphia, Pennsylvania, USA.

29 ¹⁰ Department of Surgery, Perelman School of Medicine at the University of Pennsylvania,
30 Philadelphia, Pennsylvania, USA.

31 ¹¹ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla,
32 California, USA.

33 ¹² Department of Medicine, Division of Infectious Diseases and Global Public Health, University
34 of California, San Diego (UCSD), La Jolla, California , USA.

35
36 ¹³ These authors contributed equally.

37 ¹⁴ Lead Contact.

38

39 Correspondence: Ali.Naji@penmedicine.upenn.edu, vbhoj@penmedicine.upenn.edu,
40 michela.locci@penmedicine.upenn.edu

41

42 **SUMMARY**

43 Vaccine-mediated immunity often relies on the generation of protective antibodies and memory B
44 cells, which commonly stem from germinal center (GC) reactions. An in-depth comparison of the
45 GC responses elicited by SARS-CoV-2 mRNA vaccines in healthy and immunocompromised
46 individuals has not yet been performed due to the challenge of directly probing human lymph
47 nodes. In this study, through a fine-needle-aspiration-based approach, we profiled the immune
48 responses to SARS-CoV-2 mRNA vaccines in lymph nodes of healthy individuals and kidney
49 transplant (KTX) recipients. We found that, unlike healthy subjects, KTX recipients presented
50 deeply blunted SARS-CoV-2-specific GC B cell responses coupled with severely hindered T
51 follicular helper cells, SARS-CoV-2 receptor-binding-domain-specific memory B cells and
52 neutralizing antibodies. KTX recipients also displayed reduced SARS-CoV-2-specific CD4 and
53 CD8 T cell frequencies. Broadly, these data indicate impaired GC-derived immunity in
54 immunocompromised individuals, and suggest a GC-origin for certain humoral and memory B cell
55 responses following mRNA vaccination.

56

57 **KEYWORDS**

58 Fine needle aspiration, Germinal Centers, Germinal Center B cells, T follicular helper cells, SARS-
59 CoV-2, mRNA vaccines, neutralizing antibodies, kidney transplant

60

61 **INTRODUCTION**

62 Messenger RNA (mRNA) vaccines have been intensively investigated over the past decade and
63 shown to successfully induce long-lasting, protective immune responses in animal models
64 (Awasthi et al., 2019; Espeseth et al., 2020; Freyn et al., 2020; Pardi et al., 2017, 2018b, 2018a;
65 Richner et al., 2017). This vaccine platform was licensed for human use for the first time during
66 the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Bettini
67 and Locci, 2021; Carvalho et al., 2021; Krammer, 2020), and much still needs to be learned about
68 the quality of the immune responses elicited by mRNA vaccines.

69 Most vaccines confer protection by eliciting antigen-specific antibodies (Abs) and memory B cells
70 (Plotkin, 2010; Sallusto et al., 2010). Abs are secreted by plasma cells and constitute a critical
71 immune endpoint of vaccination, as they can potentially neutralize pathogens and prevent
72 infections. Equally important are memory B cells that act as a second line of defense and rapidly
73 give rise to a quick burst of Ab-secreting plasma cells if the pathogens break through the
74 “protective wall” of the pre-existing Abs. Plasma cells and memory B cells are commonly
75 generated during germinal center (GC) reactions (Allen et al., 2007; Mesin et al., 2016) in vaccine-
76 draining lymph nodes. In GCs, pathogen-activated B cells first undergo mutations in their
77 immunoglobulin genes. Next, the high-affinity GC B cell clones resulting from this somatic
78 hypermutation (SHM) process are positively selected, and ultimately differentiate into long-lived
79 plasma cells and memory B cells. GC reactions are orchestrated by T follicular helper (Tfh) cells,
80 specialized CD4 T cells that deliver a variety of signals shaping the fate of GC B cells (Crotty,
81 2019; Vinuesa et al., 2016). We and others have previously demonstrated that, in mice, mRNA
82 vaccines can elicit potent GC responses that were closely intertwined with an efficient induction
83 of SARS-CoV-2-specific binding-Abs, neutralizing (nAbs), and memory B cells (Lederer et al.,
84 2020; Tai et al., 2020; Vogel et al., 2021). These data suggest that GC reactions might be crucial
85 for the formation of durable nAb and memory B cells following SARS-CoV-2 vaccination. In line
86 with these animal data, several studies have characterized the immune responses to the SARS-
87 CoV-2 mRNA vaccines in humans and found a robust induction of nAbs and memory B cells
88 (Bettini and Locci, 2021; Collier et al., 2021; Edara et al., 2021; Goel et al., 2021; Jackson et al.,
89 2020; Planas et al., 2021; Sahin et al., 2020; Stamatatos et al., 2021; Walsh et al., 2020; Wang et
90 al., 2021; Widge et al., 2020). However, with only one exception (Turner et al., 2021), all published
91 human vaccine studies focused on the analysis of the immune responses measurable in peripheral
92 blood. Hence, a deep evaluation of the GC reactions driven by SARS-CoV-2 mRNA vaccines in
93 human, including their connection with nAbs and memory B cells, is still missing.

94 Another major question that warrants further investigation is whether SARS-CoV-2 mRNA
95 vaccines can successfully promote high-quality immune responses in individuals lacking a fully
96 functional immune system. Analyses of blood samples from recipients of solid organ transplants
97 (SOT) who underwent SARS-CoV-2 vaccination yielded mixed results (Benotmane et al., 2021;
98 Boyarsky et al., 2021a, 2021b; Cucchiari et al., 2021; Kamar et al., 2021; Massa et al., 2021;

99 Rincon-Arevalo et al., 2021). Some of these studies suggested that a large fraction of SOT
100 recipients can still generate detectable SARS-CoV-2 binding Ab titers, whereas others indicate
101 that SOT recipients completely fail to produce B cell responses and Abs to SARS-CoV-2 mRNA
102 vaccines. A common denominator, however, is the heavily curtailed nAb production in SOT
103 recipients following immunization. While the evidence from studies conducted with blood samples
104 hints at crippled GC formation, the exploration of GC responses to SARS-CoV-2 mRNA
105 vaccination in SOT recipients still remains an uncharted territory.

106 Herein, by deploying a fine-needle aspiration (FNA) approach (Havenar-Daughton et al., 2020),
107 we evaluated the GC responses elicited by SARS-CoV-2 mRNA vaccines in draining lymph nodes
108 of healthy donors (HDs) and KTX recipients and assessed their connection to humoral and memory
109 B cell responses. Our study uncovered a potent elicitation of SARS-CoV-2 full-length spike (Full
110 S) and receptor binding domain (RBD)-specific GC B cells localized in vaccine-draining lymph
111 nodes upon primary immunization of healthy individuals, which was further enhanced by the
112 booster vaccination. Furthermore, SARS-CoV-2-specific GC B cell responses were associated
113 with a robust induction of Tfh cells, RBD-specific memory B cells and nAbs. These findings were
114 in stark contrast to a profound impairment of the GC responses in KTX recipients, which were
115 coupled to a nearly-abolished RBD-specific memory B cell response and nAb formation and
116 opposed to a measurable generation of S-specific memory B cells binding Full S outside the RBD
117 region. Overall, this study shows that, in individuals with an intact immune system, RBD-specific
118 memory B cells and nAbs are efficiently induced by SARS-CoV-2 mRNA vaccination and might
119 have a GC origin. Conversely, these responses are not efficiently generated following vaccination
120 in individuals receiving immunosuppressant drugs. This study has important implications for
121 guiding future studies aimed at unraveling human immune responses after vaccination and for
122 supporting the decision to perform additional booster immunizations against SARS-CoV-2 in
123 people with a compromised immune system.

124

125 **RESULTS**

126 **Robust SARS-CoV-2-specific GC B cell responses are elicited by mRNA vaccines and**
127 **localized in draining lymph nodes of immunocompetent individuals.**

128 GC B cells and Tfh cells induced by vaccination/infection are only present in lymphoid tissues and
129 cannot be studied in blood (Vella et al., 2019). To address this issue, we conducted a human study
130 where lymphoid tissue immune responses elicited by SARS-CoV-2 mRNA vaccines were probed
131 in healthy individuals via fine-needle aspiration (FNA). The FNA approach has been successfully
132 used to track GC B cell responses to vaccination in humans, and is a relatively simple procedure
133 carrying minimal risk that does not alter the architecture of lymph nodes (Havenar-Daughton et
134 al., 2020; Turner et al., 2020, 2021). 15 healthy subjects (23-76 years old) were enrolled in this
135 study prior to vaccination with BNT162b2 or mRNA-1273 (Table 1). FNA samples were collected
136 two weeks after the first immunization (V2: day 14 +/- 2) and eight days after the booster
137 immunization (V3: day 8 +/- 2) (Figure 1A). Matched blood samples were also obtained at the
138 same time points and before vaccination (V1). Axillary draining lymph nodes from the same arm
139 where the vaccines were administered (ipsilateral) were visualized by ultrasound to guide the FNA
140 procedure (Figure 1B and Supplementary Video 1). In healthy subjects, the number of live cells
141 recovered from the FNA procedure ranged from 0.3 to 40 x 10⁶ cells. A 23-parameter flow
142 cytometry assay was performed on FNA samples to profile the immune responses induced by
143 vaccination. GC B cells were defined as class-switched B cells co-expressing CD38, low-
144 intermediate levels of CD27 and the signature transcription factor BCL6 (Figure 1C and Figure
145 S1A). Pre-pandemic tonsil samples, which are highly enriched in GCs, and putative quiescent
146 cadaveric lymph nodes from SARS-CoV-2 negative individuals were used as positive and negative
147 controls, respectively. SARS-CoV-2 mRNA vaccination elicited detectable GC B cell responses
148 after primary immunization, which were further enhanced by the booster vaccination (Figure 1C).
149 The increase in GC B cell frequencies was measurable when the responses were evaluated
150 following a longitudinal (11 individuals) or an orthogonal (15 individuals) approach (Figures 1D
151 and S1B). No correlation between age and GC B cell frequencies was observed (Figure S1C).
152 Next, by using a combination of fluorescently-labelled SARS-CoV-2 Full S and RBD tetrameric
153 probes, we identified SARS-CoV-2-specific GC B cells as GC B cells binding the Full S but not
154 the RBD probes (Full S⁺RBD⁻) or simultaneously binding the Full S and RBD probes (Full S⁺
155 RBD⁺), while failing to bind an irrelevant tetrameric probe (influenza hemagglutinin, HA from

156 A/Puerto Rico/8/34) (Figure 1E and Figure S1A). The specificity of the probes is indicated by the
157 lack of Full S and RBD-specific GC B cells in pre-pandemic tonsil samples (Figure 1E). Overall,
158 a boost in both Full S RBD⁻ and RBD⁺ GC B cell frequencies following the second vaccine dose
159 was observed, especially when a longitudinal evaluation was performed (Figure 1F and S1D).
160 Similar to total GC B cells, SARS-CoV-2-specific GC B cells did not correlate with age (Figure
161 S1E-F). Next, to determine if mRNA vaccine-induced GC responses were detectable in non-
162 draining lymph nodes, we collected contralateral axillary lymph nodes, which do not directly drain
163 the mRNA vaccines from the injection site, from a few vaccinees after the booster immunization
164 (n=4). When compared to the matched ipsilateral lymph nodes, the contralateral lymph nodes
165 displayed a trend for lower frequencies of GC B cells (Figure 1G-H), which were not SARS-CoV-
166 2 specific (Figure 1I-J). Overall, these data demonstrate that, in immunocompetent subjects,
167 SARS-CoV-2 mRNA vaccines efficiently elicit antigen-specific GC B cell responses that are
168 enhanced by a booster immunization and localized in the ipsilateral axillary draining lymph nodes.

169

170 **Tfh responses are detectable in draining lymph nodes of immunocompetent individuals upon**
171 **SARS-CoV-2 mRNA vaccination.**

172 Tfh cells are CD4 T cells specialized in regulating GC responses. By enabling the selection of high
173 affinity GC B cells and curbing the magnitude of GC reactions, Tfh cells modulate affinity
174 maturation in infection and vaccination (Crotty, 2019). We measured the frequency of GC Tfh
175 cells (referred to as Tfh cells) defined by the signature markers CXCR5 and PD-1 (Figures 2A and
176 S2A). Expression of the lineage-defining transcription factor BCL6 confirmed the identity of this
177 CXCR5^{hi}PD-1^{hi} cell population as Tfh cells (Figure 2B). As anticipated, negligible Tfh cell
178 frequencies were found in putative quiescent lymph nodes from cadaveric donors (Figure S2B)
179 and the contralateral lymph nodes of vaccinees (Figure 2A), in contrast to a more abundant Tfh
180 cell presence in tonsils (Figure S2B). Of note, the frequencies of Tfh cells in draining lymph nodes
181 of vaccinated healthy subjects had a trend for higher values than in contralateral lymph nodes
182 (p=0.056, Figure 2C) and increased after the second vaccine dose (Figures 2D and S2C). Tfh cells
183 are a functionally heterogeneous population that, in humans, is often functionally stratified by
184 chemokine receptor expression based on extensive work performed on human circulating Tfh cells

185 (Ueno, 2016). CXCR3-expressing Tfh cells are Th1-polarized (Locci et al., 2013; Morita et al.,
186 2011). By contrast, CXCR3⁻ Tfh cells can be distinguished by CCR6 expression into Th2 (CCR6⁻
187) and Th17 (CCR6⁺)-polarized cells (Morita et al., 2011). CCR4 was also used in this analysis to
188 help refine the delineation of Th2 (CCR6⁻CCR4⁺) and Th17 (CCR6⁺CCR4⁺)-biased cells (Figure
189 2E) (Acosta-Rodriguez et al., 2007). This analysis approach showed that the Tfh cells present in
190 the draining lymph nodes of vaccinees comprised Th1 and Th2-polarized Tfh cells, but not Th17-
191 biased Tfh cells (Figure 2F). Of note, Tfh cells present in vaccine draining lymph nodes correlated
192 with both Full S⁺ RBD⁻ GC B cells and RBD-specific GC B cells (Figure 2G). While bona fide
193 Tfh cells can be found exclusively in secondary lymphoid organs (Vella et al., 2019), a small
194 population of circulating activated Tfh cells expressing high levels of ICOS, PD-1 and CD38 has
195 been described in peripheral blood of vaccinated individuals for a short period of time post
196 vaccination (Bentebibel et al., 2013; Heit et al., 2017; Herati et al., 2014). In parallel to our FNA
197 analysis, we evaluated activated Tfh cell frequencies in blood of the same immunocompetent
198 subjects vaccinated with SARS-CoV-2 mRNA vaccines. The percentages of blood activated Tfh
199 cells (CD4⁺CD45RA⁻CXCR5⁺ICOS^{hi}PD-1^{hi}), a large fraction of which also expressed CD38, were
200 significantly increased by SARS-CoV-2 mRNA vaccination (Figure 2H and S2D) and did not
201 correlate with bona fide Tfh cells (gated with a similar strategy) in vaccine draining lymph nodes
202 (Figure 2I). It is worth noting that blood Tfh cells did not correlate with the frequency of SARS-
203 CoV-2-specific GC B cells (Figure S2E), indicating that, although they might reflect the presence
204 of an ongoing GC reaction, they are not accurate biomarkers to estimate bona-fide GC B and Tfh
205 cell responses. Hence GC responses are best studied by direct investigation of vaccine draining
206 lymph nodes.

207

208 **Vaccination with SARS-CoV-2 mRNA vaccines leads to the generation of memory B cells**
209 **and plasmablasts in draining lymph nodes of healthy subjects.**

210 As GCs are important for the generation of memory B cells, we next evaluated the memory B cell
211 responses elicited by the two doses of SARS-CoV-2 mRNA vaccines in immunocompetent
212 individuals. Class-switched memory B cells were first defined as IgD⁻IgM⁻CD38⁻CD27⁺ B cells
213 (Figures 3A and S1A). Next, SARS-CoV-2 Full S-specific memory B cells were stratified into

214 RBD⁻ and RBD⁺ cells (Figure 3B), as previously described for GC B cells (Figure 1E). A paired
215 (longitudinal) analysis of matched FNA samples highlighted the generation of Full S and RBD-
216 specific memory B cells after the first vaccine dose, which was significantly higher after the
217 administration of a second mRNA vaccine dose (Figure 3C). An orthogonal analysis approach
218 confirmed similar trends (Figure S3A). SARS-CoV-2-specific memory B cells were also
219 detectable at low frequencies in healthy vaccinee peripheral blood samples after two
220 immunizations (Figure S3B), and only S-specific RBD⁻, but not RBD-specific memory B cell in
221 peripheral blood correlated with the respective SARS-CoV-2-specific memory B cell populations
222 in FNAs (Figure S3C). A population of plasmablasts was also measurable by flow cytometry as
223 IgD⁺IgM⁺CD38^{hi}CD20^{lo/-} cells (Figure 3D). This population was more abundant after the booster
224 immunization (Figures 3D-E) and was also detectable at variable levels in peripheral blood
225 samples of vaccinated healthy donors (Figure S3D). However, no correlation was found between
226 the plasmablast populations detected in FNA and blood samples (Figure S3E). In sum, the data
227 obtained in our study indicate that two doses of SARS-CoV-2 mRNA vaccines can elicit SARS-
228 CoV-2 S- and RBD-specific memory B cells as well as a population of plasma cells in vaccine
229 draining lymph nodes.

230

231 **A failure to induce GC B cells by SARS-CoV-2 mRNA vaccines is associated with hindered**
232 **memory B cell and nAb responses in kidney transplant recipients.**

233 We then sought to determine the capacity of immunocompromised individuals to form GC
234 responses to SARS-CoV-2 mRNA vaccines. To this end, 13 individuals who underwent kidney
235 transplant were enrolled. Due to withdrawal of consent (n=1), failure to undergo collection
236 procedures (n=1), and lack of sufficient cells for analysis (n=1), 10 patients who were a median
237 12.6 months post-transplant (range -0.3-63 months) were included in further analysis (Table 1).
238 Although the draining lymph nodes of KTX recipients were not significantly smaller than HDs
239 (data not shown), the FNA cell recovery yield was scarcer in KTX recipients and, due to limited
240 cell recovery, the immunophenotyping was feasible in this group only at certain time points (Figure
241 S4A). The class-switched B cell populations captured by our 23-color flow cytometry analysis
242 were visualized by a dimensionality-reduction approach (Figure 4A). The most striking

243 observation emerging from this analysis was that a large cell population, reminiscent of GC B cells
244 ($CD38^+CD27^{lo/int}BCL6^+$) and present in immunocompetent individuals, was completely lacking in
245 KTX recipients. We further corroborated this finding by a direct evaluation of GC B cell
246 frequencies in KTX patients. This analysis demonstrated an almost complete failure of KTX
247 patients to form GC B cell responses after one or two immunizations with SARS-CoV-2 mRNA
248 vaccines (Figure 4B-C). Importantly, the generation of SARS-CoV-2-specific GC B cells in
249 response to vaccination was completely abrogated even in the few KTX recipients who could
250 mount low but detectable GC B cell responses (Figure 4D).

251 We next questioned whether the dramatic reduction in SARS-CoV-2-specific GC B cells was
252 associated with impaired memory B cell responses to the vaccine, as GCs are an important source
253 for memory B cell production (Mesin et al., 2016). SARS-CoV-2-specific memory B cell
254 frequencies were determined in draining lymph nodes and blood samples. Unexpectedly, the
255 analysis of FNA samples and blood peripheral mononuclear cells (PBMCs) from KTX patients
256 revealed a detectable frequency of Full S^+RBD^- memory B cells within total B cells after the
257 booster immunization as opposed to a complete lack of Full S^+RBD^+ memory B cells (Figure 4E
258 and S4B). When analyzed as frequency of memory B cells, however, Full S^+RBD^- memory B cells
259 were decreased in comparison to HDs (Figure S4C). These data, along with the fact that most
260 patients are lymphopenic, indicate that KTX recipients can respond to SARS-CoV-2 mRNA
261 vaccine by producing detectable yet reduced frequencies of Full S-specific memory B cells
262 targeting regions outside RBD. Conversely, they cannot produce measurable RBD-specific
263 memory B cell responses. Interestingly, when HDs and KTX recipients were analyzed together, a
264 strong correlation was found between lymphoid tissue RBD-specific memory B cells and GC B
265 cells, while Full S^+RBD^- memory B cells and GC B cells only presented a weak correlation (Figure
266 S4D). Overall, these intriguing observations suggest that RBD-specific, but not all Full S-specific
267 memory B cells might have a GC origin.

268 Next, we asked whether and how the absence of vaccine-induced GC B cell responses in KTX
269 recipients might be connected to altered humoral responses, which were previously reported by
270 other groups in a fraction of KTX recipients (Benotmane et al., 2021; Boyarsky et al., 2021a;
271 Kamar et al., 2021; Massa et al., 2021; Stumpf et al., 2021). As a first step in this direction, we
272 evaluated plasmablast frequencies after SARS-CoV-2 vaccine administration. Plasmablast

273 abundance among FNA and PBMC samples was increased after two immunizations with SARS-
274 CoV-2 mRNA in HDs, whereas KTX plasmablast frequencies were, for the most part, reduced in
275 both locations and time points analyzed (Figure 4F and S4E). In line with these data, only ~40-
276 50% of the KTX recipients in our FNA cohort produced Full S- and RBD-specific IgG within the
277 lower range of HDs after two immunizations, whereas the remaining ~60-50% of the patients had
278 SARS-CoV-2 binding Abs below the limit of detection (Figure 4G-H). To shed light on the quality
279 of the Ab responses driven by SARS-CoV-2 vaccination in KTX patients after two vaccine doses,
280 we measured SARS-CoV-2 nAbs by pseudotyped lentivirus-based *in vitro* assays. In these assays,
281 the large majority of HD samples collected after two vaccine doses could efficiently neutralize a
282 pseudovirus containing the D614G mutation (Figure 4I) and, less efficiently, a pseudovirus
283 containing the mutation of the SARS-CoV-2 beta strain (Figure 4J). By contrast, KTX patients
284 presented greatly diminished nAbs against D614G-pseudovirus, and KTX plasma could not
285 efficiently block the pseudovirus containing the SARS-CoV-2 beta strain mutations. Correlative
286 analysis including all donors showed that SARS-CoV-2 binding Abs and nAb titers in response to
287 SARS-CoV-2 vaccination were strongly associated with the frequency of Full S RBD⁻ and RBD⁺
288 GC B cells (Figure S4F-G). Furthermore, while bona fide Tfh cells also displayed a positive
289 correlation with nAb levels, blood activated Tfh cells did not (Figure S4H). Overall, our data
290 demonstrate that KTX recipients cannot mount SARS-CoV-2 specific GC B cell responses or
291 generate RBD-specific memory B cells and efficient nAbs after administration of mRNA vaccines.
292 Furthermore, our work points to a possible connection between GC formation, humoral responses
293 and RBD-specific memory B cell generation in SARS-CoV-2 vaccination.

294

295 **Kidney transplant recipients fail to efficiently produce T follicular helper cells and SARS-** 296 **CoV-2-specific T cell responses.**

297 Next, we aimed at determining whether KTX recipients are capable of generating T cell responses
298 to the vaccines, which could counterbalance the impaired B cell responses observed in these
299 patients (Figure 4). As GC B cell responses were heavily impaired in KTX recipients, we predicted
300 reduced Tfh cell frequencies in the KTX group. As anticipated, a viSNE analysis of antigen-
301 experienced CXCR5⁺ CD4 T cells in FNA samples revealed a deep reduction of a cell population

302 expressing the Tfh cell signature markers PD-1, BCL6 and ICOS in the KTX group (Figure 5A).
303 Concordantly, a significant reduction of Tfh cells in KTX patients in comparison to HDs also
304 emerged by a direct flow cytometry analysis (Figures 5B-C).

305 We then asked whether KTX recipients are, more broadly, incapable of mounting efficient antigen-
306 specific T cell responses to the SARS-CoV-2 mRNA vaccines. Since a direct evaluation of SARS-
307 CoV-2-specific T cells in vaccine-draining lymph nodes was not feasible due to the paucity and
308 variability in cell recovery of FNAs, we measured the frequency of SARS-CoV-2-specific CD4
309 and CD8 T cells in peripheral blood of 11 HDs and 10 KTX recipients via an Activation Induced
310 Marker (AIM) assay following *in vitro* stimulation with a SARS-CoV-2 peptide megapool of 253
311 overlapping 15-mers spanning the Spike protein (Grifoni et al., 2020a). The clinical features of the
312 subjects included in this study are presented in Table 2. Similar to what has previously been
313 reported (Apostolidis et al., 2021; Painter et al., 2021), we detected significantly increased
314 frequencies of AIM⁺ (CD200⁺CD40L⁺) SARS-CoV-2-specific CD4 T cells in blood samples of
315 all HDs after the first vaccine administration (Figure 6A-B and Figure S5A). These appeared to be
316 further boosted by the second vaccine administration, as has been observed in other studies
317 (Apostolidis et al., 2021; Painter et al., 2021), although this did not reach statistical significance in
318 our cohort. In contrast, we observed a severely reduced induction of antigen-specific CD4 T cells
319 in KTX recipients after either vaccine administration. Since KTX recipients might present altered
320 ratios of naïve/antigen-experienced CD4 T cells, we also analyzed the AIM⁺ CD4 T cells as
321 frequency of total CD4 T cells, observing a similar attenuation of SARS-CoV-2-specific CD4 T
322 cells in the KTX group compared to HDs (Figure S5B). A functional stratification of the AIM⁺
323 CD4 T cells based on chemokine receptor expression allowed us to identify SARS-CoV-2-specific
324 circulating Tfh cells (CXCR5⁺), as well as Th1 (CXCR3⁺), Th17 (CCR6⁺) and Th2 (CXCR3-
325 CCR6⁻)-polarized CXCR5⁻ non-Tfh cells (Figure 6C) (Acosta-Rodriguez et al., 2007; Morita et
326 al., 2011; Trifari et al., 2009). As previously observed, healthy individuals predominantly generate
327 SARS-CoV-2-specific circulating Tfh and Th1 polarized CD4 T cells in response to the mRNA
328 vaccines (Figure 6C-D) (Apostolidis et al., 2021; Painter et al., 2021). Low frequencies of antigen-
329 specific Th2-biased CD4 T cells were also present. Of note, the SARS-CoV-2-specific circulating
330 Tfh cells detected in HDs via the AIM assay presented a mixed Th1/Th2 functional polarization
331 (Figure 6E) similar to what was observed in draining lymph node bona fide Tfh cells (Figure 2F).

332 In the few KTX recipients that had detectable AIM⁺ cells after two vaccinations, we did not
333 observe major alterations in the functional polarization of SARS-CoV-2-specific CD4 T cells
334 (Figure S5C-D), though the small numbers of AIM⁺ CD4 T cells in these donors prevented us from
335 making definitive conclusions. The analysis of SARS-CoV-2-specific CD8 T cells followed a
336 similar trend to that observed for CD4 T cell responses. SARS-CoV-2-specific CD8 T cells,
337 defined either as CD8 T cells co-expressing 41BB and IFN γ or expressing 3 out of 5 AIM markers
338 used in our panel, were variable in frequency but detectable in most healthy vaccinees above pre-
339 vaccine baseline levels (Figures 6F-H and S5E-F). In contrast, most KTX recipients did not present
340 detectable SARS-CoV-2-specific CD8 T cells, resulting in significantly reduced responses
341 compared to HDs at both post-vaccine time points (Figure 6F-H and S5E-F). As opposed to the
342 altered antigen-specific T cell responses, we observed similar frequencies of total (non-antigen-
343 specific) CD4 T cell subsets across all time points in both HDs and KTX recipients (Figure S5G-
344 H). Altogether, these data point to severely decreased SARS-CoV-2-specific CD4 and CD8 T cell
345 responses in KTX after two immunizations with SARS-CoV-2 mRNA vaccines.

346

347 **DISCUSSION**

348 mRNA vaccines are a novel vaccine platform that has only been recently approved for human use
349 during the current coronavirus disease 2019 (COVID-19) pandemic. While it is emerging that
350 SARS-CoV-2 mRNA vaccines are highly efficient at inducing robust nAbs and memory B cell
351 responses, we still have limited knowledge of the underlying mechanisms leading to the generation
352 of such immune responses in humans. Specifically, a fundamental open question is whether nAb
353 and memory B cell generation during SARS-CoV-2 mRNA vaccination is connected to the
354 formation of GCs, microanatomical structures in secondary lymphoid organs harboring the
355 generation of affinity matured Ab-secreting cells and memory B cells. The study of vaccine-
356 induced GC reactions in humans is heavily constrained when blood, the most easily obtainable
357 human material, is the only available sample because bona fide GC B cells and Tfh cells are only
358 present in secondary lymphoid organs (Vella et al., 2019). Surrogate biomarkers such as blood
359 CXCL13 and circulating activated Tfh cells have been used thus far to predict the magnitude of
360 ongoing GC responses (Havenar-Daughton et al., 2016; Vella et al., 2019). However, these

361 biomarkers present significant shortcomings when trying to directly assay GC responses including
362 the fact that they are traceable for only short windows of time in blood, are not detectable in all
363 individuals in response to vaccination, and have not been successfully used to fully predict broad
364 qualitative aspects of GC reactions, such as the antigen specificity of GC B cells and their
365 connection to GC-derived B cell responses (Bentebibel et al., 2013; Havenar-Daughton et al.,
366 2016). These limitations emphasize the need for directly probing GC responses by adopting
367 minimally invasive approaches, such as fine-needle-aspiration, that allow longitudinal sampling
368 of the vaccine draining lymph nodes without requiring their surgical excision. Only two published
369 studies ever described human GC responses to vaccination (against influenza or SARS-CoV-2) in
370 humans by using the FNA technique (Turner et al., 2020, 2021). One study (Turner et al., 2021),
371 reported S-specific GC B cell responses to SARS-CoV-2 mRNA vaccination in lymph nodes, but
372 did not investigate the generation of RBD-specific GC B cells or the connection between SARS-
373 CoV-2-specific GC B cells and Tfh cells, nAbs, and SARS-CoV-2-specific memory B cells. Our
374 study sought to address these open questions by performing an in-depth profiling of the GC
375 responses elicited by SARS-CoV-2 mRNA vaccines directly in lymphoid tissue. We found that
376 these vaccines prompted the formation of robust Full S and RBD-specific GC B cell as well as Tfh
377 cell responses localized in draining axillary lymph nodes. Importantly, our study revealed that
378 lymphoid tissue SARS-CoV-2-specific GC B cell populations were strongly associated with the
379 ability to produce SARS-CoV-2 nAbs, as further supported by the evidence that
380 immunosuppressed individuals, who cannot form GCs, present a deeply blunted nAb production
381 (Results in KTX are discussed at length below). Although to a lower degree, we also found that
382 bona fide Tfh cells in draining lymph nodes correlated with nAb production, while activated Tfh
383 cells in blood were a less reliable predictor of nAb generation. Additionally, in our study GC
384 formation appeared to be tightly connected with the capacity to produce RBD-specific memory B
385 cells. These findings, which we would have been unable to observe by studying blood alone,
386 provide valuable insights on the otherwise poorly understood processes by which nAbs and
387 memory B cells are formed in humans after immunization with SARS-CoV-2 mRNA vaccines.

388 SARS-CoV-2-specific Abs, including nAbs, play a key role in the protection against COVID-19,
389 as indicated by passive transfer experiments in animal models (McMahan et al., 2021; Rogers et
390 al., 2020; Zost et al., 2020) and prospective cohort studies in previously-infected or vaccinated
391 humans (Bergwerk et al., 2021; Earle et al., 2021; Khoury et al., 2021; Lumley et al., 2020).

392 Herein, we have observed a strong association between SARS-CoV-2-specific GC B cells and
393 nAbs, which suggests that GC responses are critical to mount a SARS-CoV-2 nAb response during
394 vaccination. In line with this connection, we have previously shown that animals immunized with
395 SARS-CoV-2 mRNA vaccines efficiently formed RBD-specific GC B cells coupled with robust
396 nAbs levels, as opposed to mice immunized with a protein RBD antigen formulated in an MF59-
397 like adjuvant, which mounted negligible GC responses and subsequently formed limited nAbs
398 (Lederer et al., 2020). It is worth noting that a similar connection between GC formation and nAb
399 production has not been observed during SARS-CoV-2 infection. Multiple groups have reported
400 that several near-germline nAbs, endowed with potent *in vitro* neutralizing activity, are elicited
401 during natural SARS-CoV-2 infection in humans (Brouwer et al., 2020; Kreer et al., 2020;
402 Schultheiß et al., 2020; Seydoux et al., 2020). The low degree of SHM of these Abs is suggestive
403 of a limited GC process involved in their generation. Similarly, a pre-print from Eisenbarth and
404 colleagues shows that Tfh cell-deficient mice, which form negligible GCs in response to SARS-
405 CoV-2 infection, present decreased yet detectable production of Abs that can neutralize SARS-
406 CoV-2 *in vitro* (Chen et al., 2021). Overall, these data indicate that GCs might not be necessary
407 to form nAbs in response to infection. This apparently discordant outcome might stem from a
408 combination of diverse factors, including a different pool of germline B cells recruited by SARS-
409 CoV-2 mRNA vaccination, but not during natural infection. Both BNT162b2 or mRNA-1273
410 vaccines encode for a prefusion stabilized version of SARS-CoV-2 Full S protein (Wrapp et al.,
411 2020) that induce nAbs more targeted to the RBD and that bind more broadly across the RBD in
412 comparison to the infection-induced nAbs (Greaney et al., 2021). The broader binding suggests
413 that, in comparison to natural infection, additional/alternative germline precursors of the nAb
414 secreting cells are recruited by SARS-CoV-2 mRNA vaccines. It is tempting to speculate that some
415 of these nAb precursors require GC reactions to produce high-affinity nAbs, as supported by the
416 finding that plasmablasts emerging from SARS-CoV-2 mRNA vaccination can present high levels
417 of SHM (Amanat et al., 2021). As alternative or complementary explanation for the GC-nAb
418 connection described in our current and previous studies, the mRNA vaccine platform might favor
419 the formation of GC-derived nAbs thanks to its strong pro-GC activity. We and others have shown
420 that the mRNA vaccine platform is very effective at promoting the formation of GC reactions in
421 animal models (Lederer et al., 2020; Lindgren et al., 2017; Pardi et al., 2018a), with a mechanism
422 that relies on an early induction of the pro-Tfh cytokine IL-6 by the lipid nanoparticle component

423 of these vaccines (manuscript under revision). The present study, along with the recently published
424 work by Ellebedy and colleagues (Turner et al., 2021), further extend our earlier observation
425 (Lederer et al., 2020) by directly showing the formation of SARS-CoV-2 specific GC B cells in
426 humans after mRNA vaccination. Hence, by eliciting effective GC responses and/or potentially
427 recruiting nAb precursors that can seed GCs, SARS-CoV-2 mRNA vaccines might
428 mechanistically rely on GC responses to effectively generate nAbs, as strongly supported by the
429 associations between GCs and nAbs found in this study.

430 The second part of our study was aimed at evaluating the GC responses in KTX recipients and
431 their association with humoral and memory B cell responses, as no study has ever evaluated B cell
432 responses in their place of origin (vaccine-draining lymphoid tissue) in immunocompromised
433 individuals. In agreement with other studies reporting that a fraction of KTX recipients can still
434 produce SARS-CoV-2-binding Abs after two immunizations with SARS-CoV-2 mRNA vaccines
435 (Benotmane et al., 2021; Boyarsky et al., 2021a; Kamar et al., 2021; Massa et al., 2021; Stumpf et
436 al., 2021), we observed that 40-50% of the KTX recipients enrolled in our FNA study produced
437 Full S- and RBD-specific IgG, albeit within the lower range of healthy controls. This finding was
438 coupled to the observation that several KTX recipients had low but detectable plasmablast
439 frequencies following the booster immunization. Of note, we also found that KTX recipients can
440 generate reduced but detectable vaccine-induced SARS-CoV-2-specific memory B cells targeting
441 the Full S protein outside the RBD region. Nonetheless, our study reported for the first time a
442 complete failure of KTX recipients in forming lymphoid tissue SARS-CoV-2-specific GC B cell
443 responses after the administration of two mRNA vaccine doses. This finding was accompanied by
444 a markedly diminished generation of RBD-specific memory B cells and SARS-CoV-2 nAbs. Two
445 other groups reported low SARS-CoV-2 vaccine-induced nAb levels in large SOT cohorts (Massa
446 et al., 2021; Rincon-Arevalo et al., 2021) and decreased presence of class-switched RBD⁺ B cells
447 (Rincon-Arevalo et al., 2021) in peripheral blood induced by two vaccine doses. Our study
448 confirms and extends this observation by suggesting that defective GC formation could be the
449 underlying culprit behind the decreased nAb and lack of RBD-specific memory B cell production
450 in KTX recipients. Overall, our study indicates that, while some residual immune response is
451 obtainable by SARS-CoV-2 mRNA vaccination, B cell responses appear to be quantitatively and
452 qualitatively curtailed in these immunocompromised subjects.

453 Given the suboptimal humoral and B cells responses of KTX recipients following SARS-CoV-2
454 mRNA vaccination, an important question is whether mRNA vaccines are capable of eliciting T
455 cell responses in immunocompromised individuals. In immunocompetent subjects, the licensed
456 mRNA vaccines predominantly promote the formation of circulating blood Tfh cells and Th1-
457 polarized CD4 T cells (Painter et al., 2021). While a limitation of our study was the inability to
458 assess SARS-CoV-2-specific T cell responses in vaccine draining lymph nodes due to the scarcity
459 of available material, we observed that KTX recipients were almost completely deprived of bona
460 fide lymph node Tfh cells after SARS-CoV-2 mRNA vaccination, which is consistent with the
461 lack of GC B cell formation in these patients that is also described in this study. In parallel, we
462 observed, consistent with other studies (Sattler et al., 2021; Stumpf et al., 2021), that SARS-CoV-
463 2-specific CD4 (including circulating Tfh cells and Th1-polarized cells) and CD8 T cell
464 populations were decreased in frequency in KTX recipients when compared to the HD group.
465 Overall, our study indicates that KTX recipients poorly respond to two immunizations with SARS-
466 CoV-2 mRNA vaccines by failing to produce efficient humoral and cellular responses, with some
467 immune responses (GC B cells, nAb RBD-specific memory B cells and SARS-CoV-2-specific T
468 cells) that were more severely affected than others (binding Abs, Full S-specific memory B cells).
469 Since an increasing body of evidence is now suggesting that the administration of a third vaccine
470 dose can significantly boost SARS-CoV-2 binding Abs and nAbs in recipients of SOT (Hall et al.,
471 2021; Kamar et al., 2021; Massa et al., 2021), it will be interesting to assess in the future whether
472 this is due to the expansion of the small pool of preexisting (Full S⁺RBD⁺) memory B cells that we
473 identified in this study, or to an increased *de novo* generation of Abs via GC reactions.

474 Suboptimal vaccine responses in organ transplant subjects receiving immunosuppressant drugs
475 was previously reported for other vaccines including influenza A/H1N1 and Hepatitis B
476 (Brakemeier et al., 2012; Broeders et al., 2011; Cowan et al., 2014; Elhanan et al., 2018; Friedrich
477 et al., 2015). Collectively, these studies reported impaired Ab production post vaccination, which
478 is reflective of a dysfunction of the immune system in individuals receiving immunosuppressant
479 drugs. The heavily diminished induction of GC B cell, memory B cell, nAb, and T cell responses
480 in our KTX patients reported by this study is likely a consequence of lymphopenia as well as
481 immunosuppression-induced immune cell dysfunction. KTX patients in this study uniformly
482 received anti-thymocyte globulin (ATG) as induction immunosuppression at the time of kidney

483 transplantation (completed within a week). Hence, an incomplete reconstitution of the T cell pool
484 following ATG administration might at least partially explain the hampered Tfh and SARS-CoV-
485 2-specific T cell responses in patients in our cohort who were recently transplanted. Additionally,
486 maintenance immunosuppression comprised prednisone, a calcineurin inhibitor and an anti-
487 metabolite. Indeed, the majority of patients were lymphopenic, as evaluated by the baseline
488 absolute lymphocyte count (8/9 in the FNA cohort, 9/11 in the blood cohort), as a consequence of
489 ATG and/or maintenance immunosuppression. Currently, there is discordant data with regard to
490 the impact of individual immunosuppressive drugs on the immune response to SARS-CoV-2
491 mRNA vaccines in SOT populations (Boyarsky et al., 2021a; Cucchiari et al., 2021; Grupper et
492 al., 2021), likely due to the diversity of pharmacologic/biologic immunosuppressive agents and
493 doses used. Due to the limited size of our cohorts, we were unable to meaningfully attribute
494 impacts of any of the individual agents on the GC process. Future studies with larger cohorts of
495 KTX recipients will be needed to address the relative contribution of ATG and immunosuppressant
496 drugs to the disrupted GC formation that we observed in these patients.

497 In sum, by directly probing GC responses at their source, we provided a unique perspective on the
498 connection between GC formation and nAb/memory B cell generation following immunizations
499 with SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Broadly,
500 this work will pave the road to future human vaccine studies aimed at untangling the origin of
501 long-lasting, protective immune responses after immunizations with different licensed-vaccines.

502

503 **ACKNOWLEDGEMENTS**

504 M.L. was supported by NIH NIAID grants R01 AI123738 and R01AI153064. This work was
505 funded by The Gift of Life Transplant Foundation (V.B. and A.N.), the National Blood Foundation
506 (V.B.), the Burroughs Wellcome Fund (V.B.), the U19AI082630 (S.E.H. and E.J.W.) and by the
507 NIH NIAID under contract Nr. 75N9301900065 (D.W., A.S.). First, the authors wish to thank all
508 of the subjects for their participation in this study. The authors also thank Dr. Fatima Amanat and
509 Dr. Florian Krammer for kindly providing the RBD protein used in this study, Diane McLaughlin
510 and Sarah Benchimol for administrative assistance, Susan Rostami for assistance with sample

511 processing, Jennifer Trofe-Clark and Gregory Malat for regulatory assistance and Moses
512 Awofolaju, Nicole Tanenbaum, and Jordan Ort for assistance with ELISAs. We thank Dr. Florin
513 Tuluc and Jennifer Murray of the CHOP Flow Cytometry core facility for technical assistance and
514 the Flow Cytometry Core at the University of Pennsylvania.

515

516 **AUTHOR CONTRIBUTIONS**

517 K.L., E.B. and M.L. performed and/or analyzed the immunophenotyping of FNA and blood
518 samples. M.P, K.P. and R.G. performed and/or analyzed AIM assays. D.A. performed statistical
519 analysis. K.A.L. and P.B. performed and/or analyzed the neutralization assays. M.W., E.M.D., S.G
520 and S.E.H. performed and/or analyzed serological data. X.X. processed blood samples. A.G.
521 provided support with Cytobank analysis. C.L.C. and N.R. provided tonsil samples. L.J. and M.R.
522 shared expertise for FNA procedures. D.W. and A.S. provided SARS-CoV-2 peptide mega-pools.
523 A.N., M.K., B.B., V.B. and K.P. supervised the recruitment of the subjects involved in the study
524 as well as FNA and blood sample collection. M.L. wrote the manuscript with help from K.L, E.B.
525 and V.B. and input from the other authors. M.L conceived and supervised the study with support
526 from E.J.W., A.N. and V.B.

527

528 **DECLARATION OF INTERESTS**

529 EJW is consulting or is an advisor for Merck, Elstar, Janssen, Related Sciences, Synthekine and
530 Surface Oncology. EJW is a founder of Surface Oncology and Arsenal Biosciences. EJW is an
531 inventor on a patent (US Patent number 10,370,446) submitted by Emory University that covers
532 the use of PD-1 blockade to treat infections and cancer. S.E.H. has received consultancy fee from
533 Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report. A.S. is a consultant
534 for Gritstone, Flow Pharma, Arcturus, Immunoscope, CellCarta, Oxford Immunotech and Avalia.

535 **FIGURE LEGENDS**

536 **Figure 1. GC B cell responses to SARS-CoV-2 mRNA vaccines are detected in ipsilateral but**
537 **not in contralateral lymph nodes of immunocompetent individuals.**

538 **(A)** Schematic of study design. Fifteen healthy donors (HD) and thirteen kidney transplant (KTX)
539 recipients volunteered to receive two-doses of either BNT162b2 or mRNA-1273. Blood was
540 collected before immunization (V1) and at approximately 14 days post-prime (V2) and 8 days
541 post-boost (V3). FNAs were collected at approximately 14 days post-prime (V2) and 8 days post-
542 boost (V3).

543 **(B)** Representative ultrasound visualization of a HD axillary lymph node probed for the FNA
544 procedure during V3 collection time point.

545 **(C) (Left)** Representative flow cytometry plots of CD38⁺CD27^{lo/int} B cells in HD FNAs at V2 and
546 V3, a pre-pandemic tonsil sample (Tonsil Control) and a putative quiescent cadaveric lymph node
547 (LN Control). **(Right)** Representative flow cytometry plots of GC B cells (CD19⁺CD4⁻CD8⁻IgM⁻
548 IgD⁻CD38⁺CD27^{lo/int}BCL6⁺) from the indicated donors. Naive B cells were used as negative
549 control population to set the BCL6 gate.

550 **(D)** Quantification of GC B cells in FNAs from HDs, displayed as a percentage of total
551 lymphocytes. Paired (longitudinal) changes between V2 and V3 are displayed.

552 **(E)** Representative flow cytometry of SARS-CoV-2 Full S⁺ RBD⁻ (CD19⁺CD4⁻CD8⁻IgM⁻IgD⁻
553 CD38⁺CD27^{lo/int}BCL6⁺HA-Full S⁺RBD⁻) and Full S⁺ RBD⁺ (CD19⁺CD4⁻CD8⁻IgM⁻IgD⁻
554 CD38⁺CD27^{lo/int}BCL6⁺HA-Full S⁺RBD⁺) GC B cells in HD FNAs at V2 and V3 and in a tonsil
555 control.

556 **(F)** Quantification of Full S⁺ RBD⁻ (**left**) and Full S⁺ RBD⁺ (**right**) GC B cells from HDs at V2
557 and V3, displayed as a percentage of GC B cells.

558 **(G)** Representative flow cytometry plots of GC B cells in draining (ipsilateral) and in non-draining
559 (contralateral) lymph nodes of HDs.

560 **(H)** Quantification of GC B cells in FNAs at V3 from HD ipsilateral and contralateral lymph nodes,
561 displayed as a percentage of total lymphocytes.

562 **(I)** Representative flow cytometry plots of antigen-specific GC B cells in ipsilateral and
563 contralateral lymph nodes at V3.

564 **(J)** Quantification of Full S⁺ RBD⁻ (**left**) and Full S⁺ RBD⁺ (**right**) GC B cells in ipsilateral and
565 contralateral lymph nodes, displayed as a percentage of GC B cells.

566 In (D and F), n = 11 donors; red data points = V2 and blue data points = V3. In (H and J), n=4
567 donors; blue data points = ipsilateral lymph node and black data points = contralateral lymph node,
568 both at V3. Statistical analysis: In (D and F), a paired Mann-Whitney U test with continuity
569 correction was performed. In (H and J), the Wald-Wolfowitz runs test was performed. * P ≤ 0.05,
570 ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.

571

572 **Figure 2. Tfh cell responses with a mixed Th1/Th2 profile are measurable in healthy subject**
573 **lymph nodes following immunization with SARS-CoV-2 mRNA vaccines.**

574 **(A)** Representative flow cytometry plots of Tfh cells (CD4⁺CD8⁻CD19⁻CD45RA⁻CXCR5^{hi}PD-1^{hi})
575 in HD FNAs at V2, V3 and from a contralateral lymph node (negative control).

576 **(B)** Expression of BCL6 in Tfh cells from the donors indicated in (A) is displayed as a histogram.

577 **(C)** Quantification of Tfh cells in ipsilateral and contralateral lymph nodes from HDs at V3,
578 displayed as percentage of CD45RA⁻ CD4 T cells.

579 **(D)** Quantification of Tfh cells in ipsilateral lymph nodes from HDs, displayed as a percentage of
580 CD45RA⁻ CD4 T cells. Paired (longitudinal) changes between V2 and V3 are depicted.

581 **(E)** Representative flow cytometry plots for defining Tfh cell subsets. CXCR5⁻CD45RA⁻ (non-
582 Tfh) were used as a control population to set the chemokine receptor gates.

583 **(F)** Quantification of Tfh cell subsets, displayed as a percentage of total Tfh cells. Tfh cells were
584 stratified into: Th1 (CXCR3⁺), Th2 (CXCR3⁻CCR4⁺CCR6⁻), and Th17 (CXCR3⁻CCR4⁺CCR6⁺).

585 Analysis was performed on samples from ipsilateral lymph nodes of HDs at V2 and V3.

586 **(G)** Spearman correlations between Tfh cells (displayed as a percentage of CD45RA⁻ cells) and
587 SARS-CoV-2-specific GC B cells (displayed as a percentage of lymphocytes) from the ipsilateral
588 lymph nodes of HDs at V2 and V3.

589 **(H)** Quantification of activated ICOS^{hi}PD-1^{hi} Tfh cells in PBMCs, displayed as a percentage of
590 CXCR5⁺ CD4 T cells. Paired (longitudinal) changes between V1, V2 and V3 are displayed.

591 **(I)** Spearman correlation between activated ICOS^{hi}PD-1^{hi} Tfh in PBMCs and bona fide ICOS^{hi}PD-
592 1^{hi} Tfh cells from draining lymph nodes (LN) of HDs at V2 and V3, both displayed as a percentage
593 of CXCR5⁺ CD4 T cells.

594 In (C), n = 4; blue data points = ipsilateral lymph node and black data points = contralateral lymph
595 node, both at V3. In (D), n = 11. In (F and G), n = 13 for V2 and V3. In (H), n = 7; white data
596 points = V1, red data points = V2 and blue data points = V3. In (I), n = 13 for V2 and n=11 for
597 V3. In (D, G, and I), red data points = V2 and blue data points = V3. Statistical analysis: In (D and
598 F), a paired (D) and an unpaired (F) Mann-Whitney U test was performed. In (C and H), the Wald-
599 Wolfowitz runs test was performed. In (G and I), correlations were determined using the
600 Spearman's *rho* with a 95% confidence interval. * P ≤ 0.05, ** P ≤ 0.01.

601

602 **Figure 3. SARS-CoV-2 mRNA vaccinations elicit antigen-specific memory B cell responses.**

603 **(A)** Representative flow cytometry of memory B cells (CD19⁺CD4⁻CD8⁻IgM⁻IgD⁻CD38⁻CD27⁺)
604 from ipsilateral lymph nodes of HDs at V2 and V3, or from a putative quiescent cadaveric lymph
605 node (LN Control).

606 **(B)** Representative flow cytometry of SARS-CoV-2-specific memory B cells (HA⁻Full S⁺RBD⁻
607 or HA⁻Full S⁺RBD⁺) from ipsilateral lymph nodes of HDs at V2 and V3, or a LN control.

608 **(C)** Quantification of Full S⁺ RBD⁻ (**left**) and Full S⁺ RBD⁺ (**right**) memory B cells from ipsilateral
609 lymph nodes of HDs, displayed as a percentage of total lymphocytes. Paired (longitudinal) changes
610 between V2 and V3 are shown.

611 **(D)** Representative flow cytometry of plasmablasts (CD19⁺CD4⁻CD8⁻IgM⁻IgD⁻CD38^{hi}CD20^{-/lo})
612 from ipsilateral lymph nodes of HDs at V2 and V3, or a LN control.

613 **(E)** Quantification of plasmablasts in ipsilateral lymph nodes from HDs, displayed as a percentage
614 of total lymphocytes.

615 In (C and E), $n = 11$; red data points = V2 and blue data points = V3. Statistical analysis: In (C and
616 E), a paired Mann-Whitney U test with continuity correction was performed. * $P \leq 0.05$, ** $P \leq$
617 0.01.

618

619 **Figure 4. Kidney transplant recipients fail to mount GC reactions and have reduced B cell**
620 **and humoral responses.**

621 **(A)** viSNE analysis of class-switched B cells ($CD19^+CD4^-CD8^-IgM^+IgD^-$) in ipsilateral lymph
622 node samples from HDs and KTX recipients at V3.

623 **(B)** Representative flow cytometry of GC B cells ($CD19^+CD4^-CD8^-IgM^+IgD^-$
624 $CD38^+CD27^{lo/int}BCL6^+$) in ipsilateral lymph node samples from HDs and KTX recipients at V3.

625 **(C and D)** Quantification of GC B cells (C) and SARS-CoV-2-specific GC B cells (D), in
626 ipsilateral lymph node samples from HDs and KTX recipients, displayed as a percentage of B
627 cells. Unpaired (orthogonal) data from V2 and V3 are displayed.

628 **(E)** Quantification of SARS-CoV-2-specific memory B cells, in ipsilateral lymph node samples
629 from HDs and KTX recipients, displayed as a percentage of B cells. Unpaired (orthogonal) data
630 from V2 and V3 are displayed.

631 **(F)** Quantification of plasmablasts, in ipsilateral lymph node samples from HDs and KTX
632 recipients, displayed as a percentage of B cells. Unpaired (orthogonal) data from V2 and V3 are
633 displayed.

634 **(G and H)** Serum concentration of Full S-specific (G) and RBD-specific (H) IgG from HDs and
635 KTX recipients measured by ELISA.

636 **(I and J)** Levels of nAbs against SARS-CoV-2 D614G (I) and Beta (J) mutants measured by
637 pseudoneutralization assay in serum samples from HDs and KTX recipients.

638 In (A), for HD and KTX n=3 at V3. In (C-F), for HD: n = 13 for at V2 and V3; For KTX: n = 3 at
639 V2 and n = 7 at V3. In (G-J), for HD: n = 12 at V1 and V2 and n = 13 at V3; For KTX: n = 7 at
640 V1, n = 2 at V2, and n = 8 at V3. In (C-J), a circle is used to represent HDs, a triangle is used to
641 represent KTX recipients, and a square is used to indicate a KTX recipient with a prior SARS-
642 CoV-2 infection. In (C-J), red data points = V2 and blue data points = V3 and in (G-J) white data
643 points = V1. Statistical analysis: In (C-J), the Wald-Wolfowitz runs test was used to perform an
644 exact comparison between the data distributions for HD versus KTX at each time point. * $P \leq 0.05$,
645 ** $P \leq 0.01$, *** $P \leq 0.001$.

646

647 **Figure 5. Tfh cell responses to mRNA vaccination are dramatically dampened in kidney**
648 **transplant recipients.**

649 (A) viSNE analysis of antigen-experienced CXCR5⁺ CD4 T cells (CD19⁻CD8⁻CD4⁺CD45RA⁻
650 CXCR5⁺) in ipsilateral lymph node samples from HDs and KTX recipients at V3.

651 (B) Representative flow cytometry of Tfh cells (CD4⁺CD8⁻CD19⁻CD45RA⁻CXCR5^{hi}PD-1^{hi}) from
652 HDs and KTX recipients at V3.

653 (C) Quantification of Tfh cells in ipsilateral lymph nodes samples from HDs and KTX recipients
654 shown as a percentage of CD4 T cells. Unpaired (orthogonal) changes between V2 and V3 are
655 displayed.

656 In (A), for HD and KTX n=3 at V3. In (C), for HD: n = 13 for V2 and V3; for KTX: n = 3 for V2
657 and n = 7 for V3; a circle is used to represent HDs, a triangle is used to represent KTX recipients,
658 and a square is used to indicate a KTX recipient with a prior SARS-CoV-2 infection; red data
659 points = V2 and blue data points = V3. Statistical analysis: In (C), a paired Mann-Whitney U test
660 with continuity correction was performed. * $P \leq 0.05$, ** $P \leq 0.01$.

661

662 **Figure 6. Kidney transplant recipients fail to generate effective antigen-specific T cell**
663 **responses.**

664 **(A)** Representative flow cytometry of AIM⁺ (CD200⁺CD40L⁺) CD4 T cells in PBMCs at V1, V2
665 and V3 from HDs and KTX recipients.

666 **(B)** Quantification of AIM⁺ CD4 T cells, defined as in (A), displayed as a percentage of antigen-
667 experienced (CD45RA⁻) CD4 T cells. Paired (longitudinal, left) or unpaired (orthogonal, right)
668 analyses of PBMC samples from HDs and KTX recipients at V1, V2 and V3 are shown.

669 **(C)** Representative gating strategy to define AIM⁺ CD4 T cell subsets in HD PBMC samples.

670 **(D and E)** Quantification of AIM⁺ total CD4 T cell subsets (D) and AIM⁺ CXCR5⁺ CD4 T cell
671 subsets (E) in HDs. Unpaired (orthogonal) analysis of PBMC samples from V1, V2 and V3 in HDs
672 is displayed.

673 **(F)** Representative flow cytometry of AIM⁺ (IFN γ ⁺ and 41BB⁺) CD8 T cells in PBMCs at V1, V2
674 and V3 from HDs and KTX recipients.

675 **(G)** Quantification of AIM⁺ (IFN γ ⁺ and 41BB⁺) CD8 T cells, displayed as a percentage of antigen-
676 experienced (CD45RA⁻) CD8 T cells. Paired (longitudinal, left) or unpaired (orthogonal, right)
677 analyses of PBMC samples from HDs and KTX recipients at V1, V2 and V3 are shown

678 **(H)** Quantification of AIM⁺ (cells expressing at least 3 of 5 activation markers: CD107a, 41BB,
679 CD200, CD40L, and IFN γ) CD8 T cells, displayed as a percentage of antigen-experienced
680 (CD45RA⁻) CD8 T cells. Paired (longitudinal, left) or unpaired (orthogonal, right) analyses of
681 PBMC samples from HDs and KTX V1, V2 and V3 recipients are shown.

682 In (B, D-E and G-H), for HD: n = 11 for V1 and V3, n = 9 for V2; for KTX: n = 5 for V1, n = 6 for
683 V2, and n = 7 for V3. In (B and G-H), a circle is used to represent HD and a triangle is used to
684 represent KTX; white data points = V1, red data points = V2 and blue data points = V3. Statistical
685 analysis: In (B-H), the Wald-Wolfowitz runs test was used to perform an exact comparison
686 between the two data distributions of interest. * P \leq 0.05, ** P \leq 0.01, *** P \leq 0.001, **** P \leq
687 0.0001.

688

689 **METHODS**

690 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

691 **Study design and human samples**

692 The prospective cohort study included 15 healthy adults and 14 kidney transplant recipients at the
693 Hospital of the University of Pennsylvania across both the lymph node and blood samples analyses
694 (**Table 1 and 2**). All participants received two doses of either BNT162b2 or mRNA-1273
695 vaccines, according to the recommended 3- and 4-week interval, respectively. All participants
696 received the first and second immunizations in the same arm. Written informed consent for
697 participation was obtained according to the Declaration of Helsinki and protocols were approved
698 by the Institutional Review Board of the University of Pennsylvania. Lymph node samples were
699 obtained by ultrasound-guided fine needle aspiration at day 12 (+/- 3 days) after primary
700 immunization and at day 10 (+/- 2 days) after booster immunization. Blood samples were obtained
701 at baseline prior to vaccination (visit 1, V1), day 12 (+/- 3 days) following primary immunization
702 (visit 2, V2), and day 10 (+/- 2 days) following booster (visit 3, V3).

703 Lymph nodes and pediatric tonsils were obtained from the National Disease Resource Interchange
704 (NDRI), and the Children's Hospital of Philadelphia (CHOP), respectively.

705

706 **Ultrasound guided fine needle aspiration**

707 All fine needle aspirations (FNA) were performed by board-certified radiologists, similar to what
708 previously described (Havenar-Daughton et al., 2020). Briefly, a Philips EPIQ ELITE or PHILIPS
709 IU222 ultrasound instrument was used to visualize axillary draining lymph nodes. The area around
710 the lymph node was anesthetized using 2-6mL of 0.9% buffered lidocaine solution. A 25-gauge
711 needle was inserted into the cortex and moved back-and-forth several times, sample was aspirated
712 and ejected into cold RPMI media containing 10% FBS. A total of five such passes were
713 performed. In all participants, FNAs were performed on the side of vaccination (ipsilateral). In 4
714 participants, additional FNA was performed on the contralateral side.

715

716 **Blood processing**

717 *Isolation of serum:* Blood was collected in serum separator tubes (Becton Dickinson) which were
718 spun at 935g for 15 minutes. Serum was collected, aliquoted, and frozen at -80°C for subsequent
719 use.

720 *Isolation of Peripheral Blood Mononuclear Cells (PBMCs):* PBMCs were isolated from blood
721 collected in sodium heparin vacutainer tubes (Becton Dickinson). Briefly, whole blood was first
722 spun at 935g for 15min. The plasma was carefully collected, aliquoted and stored at -80°C. The
723 buffy layer and red cell sediment were diluted with an equal volume of RPMI with 5% FBS
724 (RPMI-5) and gently layered over 15mL of Ficoll-Paque Plus (Cytiva) in a 50mL SepMate tube
725 (STEMCELL Technologies). The sample was centrifuged at 1200g for 10 minutes. The PBMC
726 were transferred into a new 50mL conical tube, centrifuged, decanted, and washed twice with
727 RPMI-5 before flow cytometry staining or cryopreservation in FBS with 10% dimethyl sulfoxide.

728

729 **Production of fluorescently labeled proteins**

730 *Labeling of SARS-CoV-2 full-length spike protein:* Full-length, biotinylated spike protein was
731 purchased from R&D Systems. Streptavidin-conjugated BV421 (Biolegend) was then added at a
732 6:1 molar ratio (biotinylated-protein to streptavidin-conjugate) on ice for 1 hour.

733 *Labeling of HA and SARS-CoV-2 RBD:* Recombinant HA and RBD was produced as previously
734 described (Amanat et al., 2020; Margine et al., 2013; Stadlbauer et al., 2020). To create
735 fluorescently labeled RBD tetramers, RBD was biotinylated using the EZ-Link Micro Sulfo-NHS-
736 Biotinylation Kit (ThermoFisher). Streptavidin-conjugated PE was then added at a 6:1 molar ratio
737 (biotinylated-protein to streptavidin-conjugate). Specifically, after the volume of fluorochrome
738 needed to achieve a 6:1 molar ratio was determined, the total volume of fluorochrome was split
739 into 10 subaliquots. These subaliquots were then added, on ice, to the biotinylated protein and
740 mixed by pipetting every 10 minutes (for a total of 10 additions).

741

742 **Flow cytometry**

743 Staining was performed on freshly isolated FNA and PBMC samples or cryopreserved control LN
744 and tonsil samples. Up to 10^6 cells were incubated with a cocktail of chemokine receptor antibodies
745 in FACS buffer (PBS containing 2% FBS and 1mM EDTA) for 10 minutes at 37°C. All remaining
746 steps were carried out at 4°C. Without washing, a 2x cocktail of all other surface antibodies diluted
747 in Brilliant Violet Staining Buffer (BD Biosciences) was added directly and incubated for 1 hour.
748 Cells were washed with FACS buffer, fixed and permeabilized with FoxP3
749 Fixation/Permeabilization Buffer (eBioSciences) according to manufacturer's instructions for 1
750 hour, and incubated with anti-BCL6 mAb (BD Biosciences) for 30 minutes. The 23-color panel
751 used in this study is described in Table 3. Samples were washed, resuspended in FACS buffer and
752 immediately acquired on an Aurora using SpectroFlow v2.2 (Cytex). Data was analyzed using
753 Flow v.10 (Treestar).

754

755 **viSNE analysis**

756 viSNE analysis was performed on Cytobank (<https://cytobank.org>).

757 *Class-switched B cell analysis:* Cells were defined as live, CD8⁻, CD4⁻, CD19⁺, IgD⁻ IgM⁻. viSNE
758 analysis was performed using 3200 cells from n = 3 donors per cohort with 5000 iterations, a
759 perplexity of 60 and a theta of 0.5. The following markers and/or probes were used to generate
760 viSNE projections: CXCR5, CD11b, CD11c, CD20, CD27, CD38, BCL6, CCR4, CCR6, CXCR3,
761 CD138, ICOS, PD-1, RBD Probe, Full S Probe, HA Probe.

762 *CXCR5⁺ CD4⁺ T cell analysis:* Cells were defined as live, CD8⁻, CD19⁻, CD4⁺, CD45RA⁻ CXCR5⁺.
763 Analysis was performed using 2730 cells from n = 3 donors per cohort with 5000 iterations, a
764 perplexity of 100 and a theta of 0.5. The following markers and/or probes were used to generate
765 viSNE projections: PD-1, BCL6, CCR4, CCR6, CXCR3, CD11b, CD11c, CD20, CD27, CD38,
766 ICOS.

767

768 **Activation induced marker (AIM) expression assay**

769 The AIM assay was performed as previously described (Painter et al., 2021). Briefly, after thawing
770 and counting, cells were resuspended in fresh R10 to a final density of 10×10^6 cells/mL, and 2×10^6
771 cells in 200 μ L were plated in duplicate wells in 96-well round-bottom plates. After resting

772 overnight, CD40 blocking antibody was added to both duplicate wells for 15 minutes prior to
773 stimulation. One of the duplicate wells was then stimulated for 24 hours with costimulation (anti-
774 human CD28/CD49d, BD Biosciences) and the Spike peptide megapool at a final concentration of
775 1 mg/mL, while the other well was treated with costimulation alone as a paired unstimulated
776 sample. The CD4-S peptide megapool consists of 253 overlapping 15-mer peptides spanning the
777 entire sequence of the Spike protein and was prepared as previously described (Grifoni et al.,
778 2020b, 2020a). The remainder of the AIM assay was performed and samples were collected and
779 analyzed as previously described (Painter et al., 2021). The flow cytometry panel used for the the
780 detection of AIM⁺ cell populations is described in Table 4.

781 AIM⁺ cells were identified from non-naïve or total T cell populations where indicated. All data
782 from AIM expression assays were background-subtracted using paired unstimulated control
783 samples. For T cell subsets, the AIM⁺ background frequency of CD45RA⁻ T cells was subtracted
784 independently for each subset. AIM⁺ CD4 T cells were defined by dual-expression of CD200 and
785 CD40L. AIM⁺ CD8 T cells were defined by either expression of 41BB and IFN γ or a boolean
786 analysis identifying cells expressing at least three of five markers: CD200, CD40L, 41BB,
787 CD107a, and intracellular IFN γ .

788 AIM assay data were visualized using RStudio. Boxplots represent median with interquartile
789 range. Source code and data files are available upon request from the authors.

790

791 **Enzyme-linked immunosorbent assay**

792 ELISAs were performed using a previously described protocol (Flannery et al., 2020). Plasmids
793 expressing the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and the full-
794 length (FL) spike protein were provided by F. Krammer (Mt. Sinai). SARS-CoV-2 RBD and FL
795 proteins were produced in 293F cells and purified using nickel–nitrilotriacetic acid (Ni-NTA)
796 resin (Qiagen). The supernatant was incubated with Ni-NTA resin at room temperature for 2 hours
797 before collection using gravity flow columns and protein elution. After buffer exchange into
798 phosphate-buffered saline (PBS), the purified protein was aliquoted and stored at -80°C . ELISA
799 plates (Immulon 4 HBX, Thermo Fisher Scientific) were coated with PBS (50 μl per well) or a

800 recombinant SARS-CoV-2 RBD or FL proteins (2 µg/ml) diluted in PBS and stored overnight at
801 4°C. ELISA plates were washed three times with PBS containing 0.1% Tween 20 (PBS-T) and
802 blocked for 1 hour with PBS-T containing 3% nonfat milk powder. Serum samples that had been
803 previously heat-inactivated (56°C for 1 hour) were serially diluted four-fold in 96-well round-
804 bottom plates in PBS-T supplemented with 1% nonfat milk powder (dilution buffer), starting at a
805 1:50 dilution. ELISA plates were then washed three times with PBS-T. 50 µl of serum dilution
806 was added to each well and incubated at room temperature for 2 hours. Plates were then washed
807 again with PBS-T three times and 50 µl of horseradish peroxidase (HRP)-labeled goat anti-human
808 IgG (1:5000; Jackson ImmunoResearch Laboratories) secondary antibodies was added. After 1-
809 hour incubation at room temperature, plates were washed three times with PBS-T, 50 µl of
810 SureBlue 3,3',5,5'-tetramethylbenzidine substrate (KPL) was added to each well, and 25 µl of 250
811 mM hydrochloric acid was added to each well to stop the reaction five minutes later. Plates were
812 read at an optical density (OD) of 450 nm using the SpectraMax 190 microplate reader (Molecular
813 Devices). All incubation and washing steps were performed using a plate mixer. For analyses, OD
814 values from the plates coated with PBS were subtracted from the OD values from plates coated
815 with either RBD or FL recombinant protein, to control for background ELISA antibody binding.
816 Each plate contained a dilution series of the IgG monoclonal antibody CR3022, which is reactive
817 to the SARS-CoV-2 spike protein, to control for variability between assays. Serum antibody
818 concentrations were reported as arbitrary units relative to the CR3022 monoclonal antibody.

819

820 **Pseudovirus neutralization assay**

821 *Production of VSV pseudotypes with SARS-CoV-2 S:* 293T cells plated 24 hours previously at 5
822 X 10⁶ cells per 10 cm dish were transfected using calcium phosphate with 35 µg of pCG1 SARS-
823 CoV-2 S D614G delta18 or pCG1 SARS-CoV-2 S B.1.351 delta 18 expression plasmid encoding
824 a codon optimized SARS-CoV2 S gene with an 18 residue truncation in the cytoplasmic tail
825 (kindly provided by Stefan Pohlmann). Twelve hours post transfection the cells were fed with
826 fresh media containing 5mM sodium butyrate to increase expression of the transfected DNA.
827 Thirty hours after transfection, the SARS-CoV-2 spike expressing cells were infected for 2-4 hours
828 with VSV-G pseudotyped VSVΔG-RFP at a MOI of ~1-3. After infection, the cells were washed
829 twice with media to remove unbound virus. Media containing the VSVΔG-RFP SARS-CoV-2

830 pseudotypes was harvested 28-30 hours after infection and clarified by centrifugation twice at
831 6000g then aliquoted and stored at -80 °C until used for antibody neutralization analysis.

832 *Antibody neutralization assay using VSVΔG-RFP SARS-CoV-2:* All sera were heat-inactivated for
833 30 minutes at 55 °C prior to use in neutralization assay. Vero E6 cells stably expressing TMPRSS2
834 were seeded in 100 µl at 2.5×10^4 cells/well in a 96 well collagen coated plate. The next day, 2-fold
835 serially diluted serum samples were mixed with VSVΔG-RFP SARS-CoV-2 pseudotyped virus
836 (100-300 focus forming units/well) and incubated for 1hr at 37 °C. Also included in this mixture
837 to neutralize any potential VSV-G carryover virus was 1E9F9, a mouse anti-VSV Indiana G, at a
838 concentration of 600 ng/ml (Absolute Antibody). The serum-virus mixture was then used to
839 replace the media on VeroE6 TMPRSS2 cells. 22 hours post infection, the cells were washed and
840 fixed with 4% paraformaldehyde before visualization on an S6 FluoroSpot Analyzer (CTL, Shaker
841 Heights OH). Individual infected foci were enumerated and the values compared to control wells
842 without antibody. The focus reduction neutralization titer 50% (FRNT₅₀) was measured as the
843 greatest serum dilution at which focus count was reduced by at least 50% relative to control cells
844 that were infected with pseudotyped virus in the absence of human serum. FRNT₅₀ titers for each
845 sample were measured in at least two technical replicates and were reported for each sample as the
846 geometric mean.

847

848 **Statistical analysis**

849 GraphPad Prism software version 9 was used for generating dot plots, bar plots and the correlation
850 images presented in this work. All statistical data analyses were carried out using R version 4.0.3.
851 The departure of the data from a normal/Gaussian distribution was confirmed by the Shapiro-Wilk
852 test and consequently, nonparametric, distribution-free tests were used for all comparisons
853 throughout this work. Single comparisons between variables were performed using the two-tailed
854 Mann-Whitney U test with continuity correction when the number of data points in each group
855 was greater than seven. Else, the Wald–Wolfowitz runs test was employed to afford greater
856 sensitivity to the analysis (Sprent, 2019). Univariate correlations involving continuous and
857 categorical data were performed using the rank-based Spearman correlation analysis. The reported
858 p-values are corrected for multiple hypothesis testing using the Benjamini-Hochberg procedure

859 (Benjamini and Hochberg, 1995). Statistical significance for all comparisons was set at the critical
860 values of $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***), and $p < 0.0001$ (****).

861 **SUPPLEMENTAL INFORMATION**

862

863 **Supplementary Figure 1. GC B cell responses to SARS-CoV-2 mRNA vaccines are detectable**
864 **in vaccine-draining ipsilateral lymph nodes.**

865 (A) Representative gating strategy for defining GC B cells (CD19⁺CD4⁻CD8⁻IgM⁻IgD⁻
866 CD38⁺CD27^{lo/int}BCL6⁺), SARS-CoV-2-specific GC B cells (CD19⁺CD4⁻CD8⁻IgM⁻IgD⁻
867 CD38⁺CD27^{lo/int}BCL6⁺HA⁻S⁺RBD^{+/-}) and memory B cells (CD19⁺CD4⁻CD8⁻IgM⁻IgD⁻CD38⁻
868 CD27⁺).

869 (B) Quantification of GC B cells from ipsilateral lymph nodes of HDs, displayed as a percentage
870 of total lymphocytes. Unpaired (orthogonal) changes between V2 and V3 are shown.

871 (C) Spearman correlation between HD age (years) and GC B cells (displayed as a percentage of
872 lymphocytes) at V2 and V3.

873 (D) Orthogonal analysis of Full S⁺ RBD⁻ and Full S⁺ RBD⁺ GC B cells from HD ipsilateral lymph
874 nodes, displayed as a percentage of GC B cells.

875 (E and F) Spearman correlation between HD age (years) and antigen-specific GC B cells
876 (displayed as a percentage of GC B cells) at V2 and V3.

877 In (B and D), n=13 for V2 and V3. In (C, E and F), n =12 for V2 and V3. In (B-F), red data points
878 = V2 and blue data points = V3. Statistical analysis: In (B and D), an unpaired Mann-Whitney U
879 test with continuity correction was performed. In (C, E and F), correlations were determined using
880 the Spearman's *rho* with a 95% confidence interval. * P ≤ 0.05.

881

882 **Supplementary Figure 2. Tfh cell frequencies increase following immunization with SARS-**
883 **CoV-2 mRNA vaccines.**

884 (A) Representative gating strategy for defining Tfh cells (CD4⁺CD8⁻CD19⁻CD45RA⁻CXCR5^{hi}PD-
885 1^{hi}).

886 **(B)** Representative flow cytometry of Tfh cells in a putative quiescent cadaveric lymph node (LN
887 Control, left) and a pre-pandemic tonsil sample (Tonsil Control, right).
888 **(C)** Orthogonal analysis of Tfh cells from HD ipsilateral lymph nodes at V2 and V3, displayed as
889 a percentage of CD45RA⁻ CD4 T cells.
890 **(D)(Left)** Representative flow cytometry of activated ICOS^{hi}PD-1^{hi} Tfh cells (CD4⁺CD8⁻CD19⁻
891 CD45RA⁻CXCR5⁺ICOS^{hi}PD-1^{hi}) from HD PBMC samples at V1, V2 and V3. **(Right)**
892 Representative plot of CD38 expression, displayed as a histogram, in ICOS^{hi}PD-1^{hi} Tfh cells.
893 **(E)** Spearman correlation between activated ICOS^{hi}PD-1^{hi} Tfh cells, defined as in (D), from
894 PBMCs (displayed as a percentage of CXCR5⁺ CD4 T cells) and antigen-specific GC B cells
895 from ipsilateral lymph nodes (displayed as a percentage of lymphocytes) of HDs at V2 and V3.
896
897 In (C), n=13 for V2 and V3. In (E), n =13 for V2 and n = 11 for V3. In (C and E), red data points
898 = V2 and blue data points = V3. Statistical analysis: In (C), an unpaired Mann-Whitney U test with
899 continuity correction was performed. In (E), correlations were determined using the Spearman's
900 *rho* with a 95% confidence interval. * P ≤ 0.05.

901

902 **Supplementary Figure 3. SARS-CoV-2 mRNA vaccines induce the generation of antigen-**
903 **specific memory B cells.**

904 **(A)** Orthogonal analysis of SARS-CoV-2-specific memory B cells from HD ipsilateral lymph
905 nodes (LNs) at V2 and V3, displayed as a percentage of lymphocytes.
906 **(B)** Orthogonal analysis of SARS-CoV-2-specific memory B cells from HD PBMCs at V2 and
907 V3, displayed as percentage of lymphocytes.
908 **(C)** Spearman correlation between SARS-CoV-2-specific memory B cells from ipsilateral lymph
909 nodes (LN) and PBMCs of HDs, both displayed as a percentage of lymphocytes.
910 **(D)** Orthogonal analysis of plasmablasts from PBMCs of HDs at V2 and V3, displayed as a
911 percentage of lymphocytes.
912 **(E)** Spearman correlation between plasmablasts from HD ipsilateral lymph nodes (LN) and
913 PBMCs at V2 and V3, both represented as a percentage of lymphocytes.

914

915 In (A and B), n=13 for V2 and V3. In (C - E), n =13 for V2 and n = 11 for V3. In (A-E), red data
916 points = V2 and blue data points = V3. Statistical analysis: In (A, B, and D), an unpaired Mann-
917 Whitney U test with continuity correction was performed. In (C and E), correlations were
918 determined using the Spearman's *rho* with a 95% confidence interval. * $P \leq 0.05$, ** $P \leq 0.01$, ***
919 $P \leq 0.001$.

920

921 **Supplementary Figure 4. Kidney transplant recipients have blunted germinal center**
922 **responses which correlates with reduced B cell and humoral responses.**

923 **(A)** Quantification of the total cell yield from ipsilateral lymph nodes (LNs) of HDs and KTX
924 recipients at V2 and V3.

925 **(B)** Quantification of SARS-CoV-2-specific memory B cells in PBMCs from HDs and KTX
926 recipients, displayed as a percentage of B cells.

927 **(C)** Quantification of SARS-CoV-2-specific memory B cells from ipsilateral lymph nodes (LN)
928 of HDs and KTX recipients, displayed as a percentage of memory B cells.

929 **(D)** Spearman correlation between SARS-CoV-2-specific memory B cells (from PBMCs) and
930 SARS-CoV-2-specific GC B cells (from ipsilateral lymph nodes, LN) from HDs and KTX
931 recipients at V2 and V3, both displayed as a percentage of B cells.

932 **(E)** Quantification of plasmablasts in PBMCs from HDs and KTX recipients, displayed as a
933 percentage of B cells.

934 **(F and G)** Spearman correlation between SARS-CoV-2 binding (F) and neutralizing (G)
935 antibodies (against the D614G mutant) and SARS-CoV-2-specific GC B cells (from ipsilateral
936 lymph nodes, displayed as a percentage of B cells) from HDs and KTX recipients at V2 and V3.

937 **(H)** Spearman correlation between neutralizing antibody titers against the D614G mutant and
938 activated ICOS^{hi}PD-1^{hi} Tfh cells from ipsilateral lymph nodes (top) or PBMCs (bottom), shown
939 as a percentage of CXCR5⁺ CD4 T cells.

940 In (A), for HD: n = 13 for V2 and V3; for KTX: n = 5 for V2 and n = 6 for V3. In (B and E), for
941 HD: n = 13 for V2 and n = 11 for V3; for KTX: n = 2 for V2 and n = 8 for V3. In (C and D), for
942 HD: n = 13 for V2 and V3; for KTX: n = 3 for V2 and n = 7 for V3. In (F-H), for HD: n = 12 for
943 V2 and V3; for KTX: n = 2 for V2 and n = 7 for V3. In (A-H), a circle is used to represent HDs, a
944 triangle is used to represent KTX recipients, and a square is used to indicate a KTX recipient with
945 a prior SARS-CoV-2 infection; red data points = V2 and blue data points = V3. Statistical analysis:
946 In (A), an unpaired Mann-Whitney U test was performed. In (B, C and E), the Wald-Wolfowitz
947 runs test was performed. In (D and F-H), correlations were determined using the Spearman's *rho*
948 with a 95% confidence interval. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.

949

950 **Supplementary Figure 5. SARS-CoV-2-specific CD4 and CD8 T cells are reduced in KTX**
951 **PBMCs**

952 **(A)** Representative flow cytometry gating strategy for AIM assays on PBMC samples.

953 **(B)** Quantification of AIM⁺ CD4 T cells as a percentage of total CD4 T cells. Paired (longitudinal,
954 left) or unpaired (orthogonal, right) analyses of PBMC samples from HDs and KTX recipients at
955 V1, V2 and V3 are shown.

956 **(C and D)** Quantification of AIM⁺ CD4 T cell subsets (C) and AIM⁺ CXCR5⁺ CD4 T cell subsets
957 (D) in PBMCs from KTX recipients, shown as a frequency of AIM⁺ CD45RA⁻ CD4 T cells.

958 **(E)** Quantification of AIM⁺ CD8 T cells (IFN- γ ⁺ 41BB⁺), shown as a percentage of total CD8 T
959 cells, in PBMC samples from HDs and KTX recipients.

960 **(F)** Quantification of AIM⁺ CD8 T cells (cells expressing at least 3 of 5 activation markers:
961 CD107a, 41BB, CD200, CD40L, and IFN- γ), shown as a percentage of total CD8 T cells, in PBMC
962 samples from HDs and KTX recipients.

963 **(G and H)** Quantification of total CD45RA⁻ CD4 T cell subsets in PBMC samples from HDs (G)
964 and KTX recipients (H), shown as a frequency of total CD45RA⁻ CD4 T cells.

965 In (B-H), for HD: n = 11 for V1 and V3, n = 9 for V2; for KTX: n = 5 for V1, n = 6 for V2, and n
966 = 7 for V3. In (B and E-F), a circle is used to represent HDs and a triangle is used to represent

967 KTX; white data points = V1, red data points = V2 and blue data points = V3. Statistical analysis:
968 In (B-H), the Wald-Wolfowitz runs test was used to perform an exact comparison between the two
969 data distributions of interest. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

970

971 **REFERENCES**

972

973 Acosta-Rodriguez, E.V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A.,
974 Sallusto, F., and Napolitani, G. (2007). Surface phenotype and antigenic specificity of human
975 interleukin 17-producing T helper memory cells. *Nature Immunology* 8, 639–646.

976 Allen, C.D.C., Okada, T., and Cyster, J.G. (2007). Germinal-Center Organization and Cellular
977 Dynamics. *Immunity* 27, 190–202.

978 Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T.H.O., Chromikova, V., McMahon, M.,
979 Jiang, K., Arunkumar, G.A., Jurczynszak, D., Polanco, J., et al. (2020). A serological assay to detect
980 SARS-CoV-2 seroconversion in humans. *Nat Med* 26, 1033–1036.

981 Amanat, F., Thapa, M., Lei, T., Ahmed, S.M.S., Adelsberg, D.C., Carreño, J.M., Strohmeier, S.,
982 Schmitz, A.J., Zafar, S., Zhou, J.Q., et al. (2021). SARS-CoV-2 mRNA vaccination induces
983 functionally diverse antibodies to NTD, RBD, and S2. *Cell* 184, 3936-3948.e10.

984 Apostolidis, S.A., Kakara, M., Painter, M.M., Goel, R.R., Mathew, D., Lenzi, K., Rezk, A.,
985 Patterson, K.R., Espinoza, D.A., Kadri, J.C., et al. (2021). Altered cellular and humoral immune
986 responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-
987 CD20 therapy. *Medrxiv* 2021.06.23.21259389.

988 Awasthi, S., Hook, L.M., Pardi, N., Wang, F., Myles, A., Cancro, M.P., Cohen, G.H., Weissman,
989 D., and Friedman, H.M. (2019). Nucleoside-modified mRNA encoding HSV-2 glycoproteins C,
990 D, and E prevents clinical and subclinical genital herpes. *Sci Immunol* 4, eaaw7083.

991 Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and
992 Powerful Approach to Multiple Testing. *J Royal Statistical Soc Ser B Methodol* 57, 289–300.

993 Benotmane, I., Gautier, G., Perrin, P., Olagne, J., Cognard, N., Fafi-Kremer, S., and Caillard, S.
994 (2021). Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in
995 Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. *Jama* 326.

996 Bentebibel, S.-E., Lopez, S., Obermoser, G., Schmitt, N., Mueller, C., Harrod, C., Flano, E.,
997 Mejias, A., Albrecht, R.A., Blankenship, D., et al. (2013). Induction of ICOS+CXCR3+CXCR5+
998 TH Cells Correlates with Antibody Responses to Influenza Vaccination. *Science Translational*
999 *Medicine* 5, 176ra32-176ra32.

- 1000 Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin,
1001 E.G., Rubin, C., Indenbaum, V., et al. (2021). Covid-19 Breakthrough Infections in Vaccinated
1002 Health Care Workers. *New Engl J Med*.
- 1003 Bettini, E., and Locci, M. (2021). SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and
1004 Beyond. *Nato Adv Sci Inst Se 9*, 147.
- 1005 Boyarsky, B.J., Werbel, W.A., Avery, R.K., Tobian, A.A.R., Massie, A.B., Segev, D.L., and
1006 Garonzik-Wang, J.M. (2021a). Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine
1007 Series in Solid Organ Transplant Recipients. *Jama 325*, 2204–2206.
- 1008 Boyarsky, B.J., Werbel, W.A., Avery, R.K., Tobian, A.A.R., Massie, A.B., Segev, D.L., and
1009 Garonzik-Wang, J.M. (2021b). Immunogenicity of a Single Dose of SARS-CoV-2 Messenger
1010 RNA Vaccine in Solid Organ Transplant Recipients. *Jama 325*, 1784–1786.
- 1011 Brakemeier, S., Schweiger, B., Lachmann, N., Glander, P., Schönemann, C., Diekmann, F.,
1012 Neumayer, H.-H., and Budde, K. (2012). Immune response to an adjuvanted influenza A H1N1
1013 vaccine (Pandemrix®) in renal transplant recipients. *Nephrol Dial Transpl 27*, 423–428.
- 1014 Broeders, N.E., Hombrouck, A., Lemy, A., Wissing, K.M., Racapé, J., Gastaldello, K., Massart,
1015 A., Gucht, S.V., Weichselbaum, L., Mul, A.D., et al. (2011). Influenza A/H1N1 Vaccine in
1016 Patients Treated by Kidney Transplant or Dialysis: A Cohort Study. *Clin J Am Soc Nephro 6*,
1017 2573–2578.
- 1018 Brouwer, P.J.M., Caniels, T.G., Straten, K. van der, Snitselaar, J.L., Aldon, Y., Bangaru, S.,
1019 Torres, J.L., Okba, N.M.A., Claireaux, M., Kerster, G., et al. (2020). Potent neutralizing antibodies
1020 from COVID-19 patients define multiple targets of vulnerability. *Science 369*, 643–650.
- 1021 Carvalho, T., Krammer, F., and Iwasaki, A. (2021). The first 12 months of COVID-19: a timeline
1022 of immunological insights. *Nat Rev Immunol 21*, 245–256.
- 1023 Chen, J.S., Chow, R.D., Song, E., Mao, T., Israelow, B., Kamath, K., Bozekowski, J., Haynes,
1024 W.A., Filler, R.B., Menasche, B.L., et al. (2021). High-affinity, neutralizing antibodies to SARS-
1025 CoV-2 can be made in the absence of T follicular helper cells. *Biorxiv 2021.06.10.447982*.
- 1026 Collier, D.A., Marco, A.D., Ferreira, I.A.T.M., Meng, B., Datir, R.P., Walls, A.C., Kemp, S.A.,
1027 Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA
1028 vaccine-elicited antibodies. *Nature 593*, 136–141.
- 1029 Cowan, M., Chon, W.J., Desai, A., Andrews, S., Bai, Y., Veguilla, V., Katz, J.M., Josephson,
1030 M.A., Wilson, P.C., Sciammas, R., et al. (2014). Impact of Immunosuppression on Recall Immune

- 1031 Responses to Influenza Vaccination in Stable Renal Transplant Recipients. *Transplantation* 97,
1032 846–853.
- 1033 Crotty, S. (2019). T Follicular Helper Cell Biology: A Decade of Discovery and Diseases.
1034 *Immunity* 50, 1132–1148.
- 1035 Cucchiari, D., Egri, N., Bodro, M., Herrera, S., Risco-Zevallos, J.D., Casals-Urquiza, J., Cofan,
1036 F., Moreno, A., Rovira, J., Banon-Maneus, E., et al. (2021). Cellular and humoral response after
1037 MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. *Am J Transplant* 21, 2727–
1038 2739.
- 1039 Earle, K.A., Ambrosino, D.M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P.B., Siber, G.R., Dull,
1040 P., and Plotkin, S.A. (2021). Evidence for antibody as a protective correlate for COVID-19
1041 vaccines. *Vaccine* 39, 4423–4428.
- 1042 Edara, V.-V., Pinsky, B.A., Suthar, M.S., Lai, L., Davis-Gardner, M.E., Floyd, K., Flowers, M.W.,
1043 Wrammert, J., Hussaini, L., Ciric, C.R., et al. (2021). Infection and Vaccine-Induced Neutralizing-
1044 Antibody Responses to the SARS-CoV-2 B.1.617 Variants. *New Engl J Med*.
- 1045 Elhanan, E., Boaz, M., Schwartz, I., Schwartz, D., Chernin, G., Soetendorp, H., Oz, A.G., Agbaria,
1046 A., and Weinstein, T. (2018). A randomized, controlled clinical trial to evaluate the
1047 immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B®, among
1048 vaccine naïve and vaccine non-responder dialysis patients. *Clin Exp Nephrol* 22, 151–158.
- 1049 Espeseth, A.S., Cejas, P.J., Citron, M.P., Wang, D., DiStefano, D.J., Callahan, C., Donnell, G.O.,
1050 Galli, J.D., Swoyer, R., Touch, S., et al. (2020). Modified mRNA/lipid nanoparticle-based
1051 vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective
1052 in rodent models of RSV infection. *Npj Vaccines* 5, 16.
- 1053 Flannery, D.D., Gouma, S., Dhudasia, M.B., Mukhopadhyay, S., Pfeifer, M.R., Woodford, E.C.,
1054 Gerber, J.S., Arevalo, C.P., Bolton, M.J., Weirick, M.E., et al. (2020). SARS-CoV-2
1055 seroprevalence among parturient women in Philadelphia. *Sci Immunol* 5, eabd5709.
- 1056 Freyn, A.W., Silva, J.R. da, Rosado, V.C., Bliss, C.M., Pine, M., Mui, B.L., Tam, Y.K., Madden,
1057 T.D., Ferreira, L.C. de S., Weissman, D., et al. (2020). A Multi-Targeting, Nucleoside-Modified
1058 mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. *Mol Ther* 28, 1569–1584.
- 1059 Friedrich, P., Sattler, A., Müller, K., Nienen, M., Reinke, P., and Babel, N. (2015). Comparing
1060 Humoral and Cellular Immune Response Against HBV Vaccine in Kidney Transplant Patients.
1061 *Am J Transplant* 15, 3157–3165.

- 1062 Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S.,
1063 Hicks, P., Meng, W., Rosenfeld, A.M., et al. (2021). Distinct antibody and memory B cell
1064 responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. *Sci*
1065 *Immunol* *6*, eabi6950.
- 1066 Greaney, A.J., Loes, A.N., Gentles, L.E., Crawford, K.H.D., Starr, T.N., Malone, K.D., Chu, H.Y.,
1067 and Bloom, J.D. (2021). Antibodies elicited by mRNA-1273 vaccination bind more broadly to the
1068 receptor binding domain than do those from SARS-CoV-2 infection. *Sci Transl Med* *13*, eabi9915.
- 1069 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings,
1070 S.A., Sutherland, A., Premkumar, L., Jadi, R.S., et al. (2020a). Targets of T Cell Responses to
1071 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*
1072 *181*, 1489-1501.e15.
- 1073 Grifoni, A., Sidney, J., Zhang, Y., Scheuermann, R.H., Peters, B., and Sette, A. (2020b). A
1074 Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune
1075 Responses to SARS-CoV-2. *Cell Host Microbe* *27*, 671-680.e2.
- 1076 Grupper, A., Rabinowich, L., Schwartz, D., Schwartz, I.F., Ben-Yehoyada, M., Shashar, M.,
1077 Katchman, E., Halperin, T., Turner, D., Goykhman, Y., et al. (2021). Reduced humoral response
1078 to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure
1079 to the virus. *Am J Transplant* *21*, 2719–2726.
- 1080 Hall, V.G., Ferreira, V.H., Ku, T., Ierullo, M., Majchrzak-Kita, B., Chaparro, C., Selzner, N.,
1081 Schiff, J., McDonald, M., Tomlinson, G., et al. (2021). Randomized Trial of a Third Dose of
1082 mRNA-1273 Vaccine in Transplant Recipients. *New Engl J Med*.
- 1083 Havenar-Daughton, C., Lindqvist, M., Heit, A., Wu, J.E., Reiss, S.M., Kendric, K., Bélanger, S.,
1084 Kasturi, S.P., Landais, E., Akondy, R.S., et al. (2016). CXCL13 is a plasma biomarker of germinal
1085 center activity. *Proceedings of the National Academy of Sciences of the United States of America*
1086 *113*, 2702–2707.
- 1087 Havenar-Daughton, C., Newton, I.G., Zare, S.Y., Reiss, S.M., Schwan, B., Suh, M.J., Hasteh, F.,
1088 Levi, G., and Crotty, S. (2020). Normal human lymph node T follicular helper cells and germinal
1089 center B cells accessed via fine needle aspirations. *J Immunol Methods* *479*, 112746.
- 1090 Heit, A., Schmitz, F., Gerds, S., Flach, B., Moore, M.S., Perkins, J.A., Robins, H.S., Aderem, A.,
1091 Spearman, P., Tomaras, G.D., et al. (2017). Vaccination establishes clonal relatives of germinal
1092 center T cells in the blood of humans. *J Exp Med* *214*, 2139–2152.

- 1093 Herati, R.S., Reuter, M.A., Dolfi, D.V., Mansfield, K.D., Aung, H., Badwan, O.Z., Kurupati, R.K.,
1094 Kannan, S., Ertl, H., Schmader, K.E., et al. (2014). Circulating CXCR5+PD-1+ response predicts
1095 influenza vaccine antibody responses in young adults but not elderly adults. *Journal of*
1096 *Immunology* (Baltimore, Md : 1950) *193*, 3528–3537.
- 1097 Jackson, L.A., Anderson, E.J., Roupheal, N.G., Roberts, P.C., Makhene, M., Coler, R.N.,
1098 McCullough, M.P., Chappell, J.D., Denison, M.R., Stevens, L.J., et al. (2020). An mRNA Vaccine
1099 against SARS-CoV-2 — Preliminary Report. *New Engl J Med* *383*, 1920–1931.
- 1100 Kamar, N., Abravanel, F., Marion, O., Couat, C., Izopet, J., and Bello, A.D. (2021). Three Doses
1101 of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. *New Engl J Med*.
- 1102 Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao, K.,
1103 Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody levels are highly
1104 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* *27*, 1205–
1105 1211.
- 1106 Krammer, F. (2020). SARS-CoV-2 vaccines in development. *Nature* *586*, 516–527.
- 1107 Kreer, C., Zehner, M., Weber, T., Ercanoglu, M.S., Gieselmann, L., Rohde, C., Halwe, S.,
1108 Korenkov, M., Schommers, P., Vanshylla, K., et al. (2020). Longitudinal Isolation of Potent Near-
1109 Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. *Cell* *182*, 843-
1110 854.e12.
- 1111 Lederer, K., Castaño, D., Atria, D.G., Oguin, T.H., Wang, S., Manzoni, T.B., Muramatsu, H.,
1112 Hogan, M.J., Amanat, F., Cherubin, P., et al. (2020). SARS-CoV-2 mRNA Vaccines Foster Potent
1113 Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation.
1114 *Immunity* *53*, 1281-1295.e5.
- 1115 Lindgren, G., Ols, S., Liang, F., Thompson, E.A., Lin, A., Hellgren, F., Bahl, K., John, S.,
1116 Yuzhakov, O., Hassett, K.J., et al. (2017). Induction of Robust B Cell Responses after Influenza
1117 mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+
1118 CXCR3+ T Follicular Helper Cells. *Front Immunol* *8*, 1539.
- 1119 Locci, M., Havenar-Daughton, C., Landais, E., Wu, J., Kroenke, M.A., Arlehamn, C.L., Su, L.F.,
1120 Cubas, R., Davis, M.M., Sette, A., et al. (2013). Human circulating PD-1+CXCR3-CXCR5+
1121 memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody
1122 responses. *Immunity* *39*, 758–769.
- 1123 Lumley, S.F., O’Donnell, D., Stoesser, N.E., Matthews, P.C., Howarth, A., Hatch, S.B., Marsden,
1124 B.D., Cox, S., James, T., Warren, F., et al. (2020). Antibody Status and Incidence of SARS-CoV-
1125 2 Infection in Health Care Workers. *New Engl J Med* *384*, 533–540.



- 1126 Margine, I., Palese, P., and Krammer, F. (2013). Expression of Functional Recombinant
1127 Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the
1128 Baculovirus Expression System. *J Vis Exp* e51112.
- 1129 Massa, F., Cremoni, M., Gerard, A., Grabsi, H., Rogier, L., Blois, M., Hassen, N.B., Rouleau, M.,
1130 Barbosa, S., Martinuzzi, E., et al. (2021). Safety and Cross-Variant Immunogenicity of a Three-
1131 Dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant Recipients. *Ssrn Electron J*.
- 1132 McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J., Peter,
1133 L., Atyeo, C., Zhu, A., et al. (2021). Correlates of protection against SARS-CoV-2 in rhesus
1134 macaques. *Nature* 590, 630–634.
- 1135 Mesin, L., Ersching, J., and Victora, G.D. (2016). Germinal Center B Cell Dynamics. *Immunity*
1136 45, 471–482.
- 1137 Morita, R., Schmitt, N., Bentebibel, S.-E., Ranganathan, R., Bourdery, L., Zurawski, G., Foucat,
1138 E., Dullaers, M., Oh, S., Sabzghabaei, N., et al. (2011). Human blood CXCR5(+)CD4(+) T cells
1139 are counterparts of T follicular cells and contain specific subsets that differentially support
1140 antibody secretion. *Immunity* 34, 108–121.
- 1141 Painter, M.M., Mathew, D., Goel, R.R., Apostolidis, S.A., Pattekar, A., Kuthuru, O., Baxter, A.E.,
1142 Herati, R.S., Oldridge, D.A., Gouma, S., et al. (2021). Rapid induction of antigen-specific CD4+
1143 T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA
1144 vaccination. *Biorxiv* 2021.04.21.440862.
- 1145 Pardi, N., Hogan, M.J., Pelc, R.S., Muramatsu, H., Andersen, H., DeMaso, C.R., Dowd, K.A.,
1146 Sutherland, L.L., Scearce, R.M., Parks, R., et al. (2017). Zika virus protection by a single low-dose
1147 nucleoside-modified mRNA vaccination. *Nature* 543, 248–251.
- 1148 Pardi, N., Hogan, M.J., Naradikian, M.S., Parkhouse, K., Cain, D.W., Jones, L., Moody, M.A.,
1149 Verkerke, H.P., Myles, A., Willis, E., et al. (2018a). Nucleoside-modified mRNA vaccines induce
1150 potent T follicular helper and germinal center B cell responses. *The Journal of Experimental*
1151 *Medicine* 215, 1571–1588.
- 1152 Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S.J., Mui, B.L., Tam, Y.K., Karikó,
1153 K., Barbosa, C.J., Madden, T.D., et al. (2018b). Nucleoside-modified mRNA immunization elicits
1154 influenza virus hemagglutinin stalk-specific antibodies. *Nat Commun* 9, 3361.
- 1155 Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M., Planchais,
1156 C., Porrot, F., Robillard, N., Puech, J., et al. (2021). Reduced sensitivity of SARS-CoV-2 variant
1157 Delta to antibody neutralization. *Nature* 1–5.

- 1158 Plotkin, S.A. (2010). Correlates of Protection Induced by Vaccination ∇ . *Clin Vaccine Immunol*
1159 *17*, 1055–1065.
- 1160 Richner, J.M., Himansu, S., Dowd, K.A., Butler, S.L., Salazar, V., Fox, J.M., Julander, J.G., Tang,
1161 W.W., Shresta, S., Pierson, T.C., et al. (2017). Modified mRNA Vaccines Protect against Zika
1162 Virus Infection. *Cell* *169*, 176.
- 1163 Rincon-Arevalo, H., Choi, M., Stefanski, A.-L., Halleck, F., Weber, U., Szelinski, F., Jahrsdörfer,
1164 B., Schrezenmeier, H., Ludwig, C., Sattler, A., et al. (2021). Impaired humoral immunity to SARS-
1165 CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. *Sci Immunol* *6*,
1166 eabj1031.
- 1167 Rogers, T.F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W., Limbo, O., Smith, C., Song, G.,
1168 Woehl, J., et al. (2020). Isolation of potent SARS-CoV-2 neutralizing antibodies and protection
1169 from disease in a small animal model. *Science* *369*, 956–963.
- 1170 Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L.M., Vormehr, M., Baum, A., Pascal,
1171 K., Quandt, J., Maurus, D., et al. (2020). COVID-19 vaccine BNT162b1 elicits human antibody
1172 and TH1 T cell responses. *Nature* *586*, 594–599.
- 1173 Sallusto, F., Lanzavecchia, A., Araki, K., and Ahmed, R. (2010). From vaccines to memory and
1174 back. *Immunity* *33*, 451–463.
- 1175 Sattler, A., Schrezenmeier, E., Weber, U.A., Potekhin, A., Bachmann, F., Straub-Hohenbleicher,
1176 H., Budde, K., Storz, E., Proß, V., Bergmann, Y., et al. (2021). Impaired humoral and cellular
1177 immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney
1178 transplant recipients. *J Clin Invest* *131*.
- 1179 Schultheiß, C., Paschold, L., Simnica, D., Mohme, M., Willscher, E., Wenserski, L. von, Scholz,
1180 R., Wieters, I., Dahlke, C., Tolosa, E., et al. (2020). Next-Generation Sequencing of T and B Cell
1181 Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of
1182 Disease. *Immunity* *53*, 442-455.e4.
- 1183 Seydoux, E., Homad, L.J., MacCamy, A.J., Parks, K.R., Hurlburt, N.K., Jennewein, M.F., Akins,
1184 N.R., Stuart, A.B., Wan, Y.-H., Feng, J., et al. (2020). Analysis of a SARS-CoV-2-Infected
1185 Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic
1186 Mutation. *Immunity* *53*, 98-105.e5.
- 1187 Sprent, P. (2019). *Data Driven Statistical Methods*.


- 1188 Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G.A., Tan, J.,
1189 Bhavsar, D., Capuano, C., Kirkpatrick, E., et al. (2020). SARS-CoV-2 Seroconversion in Humans:
1190 A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. *Curr Protoc*
1191 *Microbiol* 57, e100.
- 1192 Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L.J., Rubin, V., Glantz, H., Neradilek, M.,
1193 Seydoux, E., Jennewein, M.F., MacCamy, A.J., et al. (2021). mRNA vaccination boosts cross-
1194 variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science* 372, 1413–1418.
- 1195 Stumpf, J., Siepmann, T., Lindner, T., Karger, C., Schwöbel, J., Anders, L., Faulhaber-Walter, R.,
1196 Schewe, J., Martin, H., Schirutschke, H., et al. (2021). Humoral and cellular immunity to SARS-
1197 CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter
1198 observational study using mRNA-1273 or BNT162b2 mRNA vaccine. *Lancet Regional Heal -*
1199 *Europe* 100178.
- 1200 Tai, W., Zhang, X., Drelich, A., Shi, J., Hsu, J.C., Luchsinger, L., Hillyer, C.D., Tseng, C.-T.K.,
1201 Jiang, S., and Du, L. (2020). A novel receptor-binding domain (RBD)-based mRNA vaccine
1202 against SARS-CoV-2. *Cell Res* 30, 932–935.
- 1203 Trifari, S., Kaplan, C.D., Tran, E.H., Crellin, N.K., and Spits, H. (2009). Identification of a human
1204 helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-
1205 17, T(H)1 and T(H)2 cells. *Nature Immunology* 10, 864–871.
- 1206 Turner, J.S., Zhou, J.Q., Han, J., Schmitz, A.J., Rizk, A.A., Alsoussi, W.B., Lei, T., Amor, M.,
1207 McIntire, K.M., Meade, P., et al. (2020). Human germinal centres engage memory and naive B
1208 cells after influenza vaccination. *Nature* 586, 127–132.
- 1209 Turner, J.S., O’Halloran, J.A., Kalaidina, E., Kim, W., Schmitz, A.J., Zhou, J.Q., Lei, T., Thapa,
1210 M., Chen, R.E., Case, J.B., et al. (2021). SARS-CoV-2 mRNA vaccines induce persistent human
1211 germinal centre responses. *Nature* 596, 109–113.
- 1212 Ueno, H. (2016). Human Circulating T Follicular Helper Cell Subsets in Health and Disease. *J*
1213 *Clin Immunol* 36, 34–39.
- 1214 Vella, L.A., Buggert, M., Manne, S., Herati, R.S., Sayin, I., Kuri-Cervantes, L., Brody, I.B.,
1215 O’Boyle, K.C., Kaprielian, H., Giles, J.R., et al. (2019). T follicular helper cells in human efferent
1216 lymph retain lymphoid characteristics. *J Clin Invest* 129, 3185–3200.
- 1217 Vinuesa, C.G., Linterman, M.A., Yu, D., and MacLennan, I.C.M. (2016). Follicular Helper T
1218 Cells. *Annual Review of Immunology* 34, 335–368.

- 1219 Vogel, A.B., Kanevsky, I., Che, Y., Swanson, K.A., Muik, A., Vormehr, M., Kranz, L.M., Walzer,
1220 K.C., Hein, S., Güler, A., et al. (2021). BNT162b vaccines protect rhesus macaques from SARS-
1221 CoV-2. *Nature* 592, 283–289.
- 1222 Walsh, E.E., Jr., R.W.F., Falsey, A.R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil,
1223 K., Mulligan, M.J., Bailey, R., et al. (2020). Safety and Immunogenicity of Two RNA-Based
1224 Covid-19 Vaccine Candidates. *New Engl J Med* 383, 2439–2450.
- 1225 Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C.O., Finkin, S., Schaefer-Babajew,
1226 D., Cipolla, M., Gaebler, C., Lieberman, J.A., et al. (2021). mRNA vaccine-elicited antibodies to
1227 SARS-CoV-2 and circulating variants. *Nature* 592, 616–622.
- 1228 Widge, A.T., Roupheal, N.G., Jackson, L.A., Anderson, E.J., Roberts, P.C., Makhene, M.,
1229 Chappell, J.D., Denison, M.R., Stevens, L.J., Pruijssers, A.J., et al. (2020). Durability of Responses
1230 after SARS-CoV-2 mRNA-1273 Vaccination. *New Engl J Med* 384, 80–82.
- 1231 Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.-L., Abiona, O., Graham, B.S., and
1232 McLellan, J.S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
1233 *Science* 367, 1260–1263.
- 1234 Zost, S.J., Gilchuk, P., Case, J.B., Binshtein, E., Chen, R.E., Nkolola, J.P., Schäfer, A., Reidy,
1235 J.X., Trivette, A., Nargi, R.S., et al. (2020). Potently neutralizing and protective human antibodies
1236 against SARS-CoV-2. *Nature* 584, 443–449.
- 1237


A




C




D




E




F




G




H





I



J









A LN: B cells


All rights reserved. No reuse allowed without permission.




C GC B Cells




D Full S+ RBD- GC B Cells




Full S+ RBD+ GC B Cells



E Full S+ RBD- Memory B Cells




Full S+ RBD+ Memory B Cells




○ HD
△ KTX


F Plasmablasts




G Full S IgG




H RBD IgG






I D614G





J Beta




○ HD
△ KTX




A PBMCs: CD4+ T cells




C




D




E



F PBMCs: CD8+ T cells



G



H

